Note: Descriptions are shown in the official language in which they were submitted.
WO 2010/060104 PCT/US2009/065797
IMPLANTABLE LIPOSOME EMBEDDED MATRIX COMPOSITION, USES
THEREOF, AND POLYCAPROLACTONE PARTICLES AS SCAFFOLDS FOR
TISSUE REGENERATION
RELATED APPLICATIONS
This application claims the benefit of priority from USSN 61/200,208, filed
November 24, 2008; USSN 61/200,213, filed November 24, 2008; USSN 61/200,207,
filed November 24, 2008; and 61/200,214, filed November 24, 2008. The contents
of
the foregoing applications are incorporated herein by reference in their
entirety.
BACKGROUND OF THE INVENTION
Delivery of bioactive molecules or chemical compounds to specific sites in
vivo
can be effected by embedding the molecules or compounds in a matrix. However,
a
common problem of matrix based delivery systems is the diffusion of compounds
embedded in the matrix into the surrounding tissue, changing the concentration
of the
compound in the matrix and affecting its bioactivity.
SUMMARY OF THE INVENTION
The present invention is based on the development of compositions and methods
for delivery of compounds encapsulated in liposomes. Embodiments of the
invention
feature liquid, semi-solid and solid matrices containing embedded liposomes,
and
methods for their formation and use. Through phagocytosis, monocytes
infiltrating the
matrix selectively incorporate the liposomes and their contents. The matrices
may be
injectable or implantable.
In exemplary embodiments, liposomes are introduced to a matrix (hydrogel) and
are embedded in the matrix. The matrix can include one or more agents for
recruiting
cells (e.g., monocytes) to the matrix. Liposomes may encapsulate agents before
being
contacted with a matrix of the invention in some embodiments. In some
embodiments, a
matrix of the invention is formulated to incorporate agents and compounds that
exert one
or more effects upon cells which infiltrate the matrix. In other embodiments,
a matrix of
the invention is formulated to incorporate agents and compounds that attract
cells (e.g.,
monocytes) to the matrix. In additional embodiments, the matrix is permeable
for cells
to enter or exit the matrix and to compounds produced by infiltrating cells.
Compounds
1
WO 2010/060104 PCT/US2009/065797
produced or secreted by cells within a matrix may diffuse out of the matrix
and create
effects in the surrounding environment in some embodiments. Additional
embodiments
of the invention include kits comprising a matrix of the invention and
instructions for
practicing the invention. In some embodiments, a kit of the invention includes
matrix
and one or more reagents for preparing liposomes for incorporation therein.
In other embodiments, the invention relates to methods of using
polycaprolactone (PCL) particles as biodegradable scaffolds in tissue
engineering
applications.
DETAILED DESCRIPTION OF THE INVENTION
1. Definitions
In order that the present invention may be more readily understood, certain
terms
are first defined.
Monocytes are mononuclear phagocytic leukocytes formed in the bone marrow
that transport to tissues where they develop into a wide variety of cells,
including
macrophages. The term "monocytic cell" as used herein refers both to monocytes
and
any cell terminally differentiated from monocytes (e.g., macrophages), as well
as cells
capable of differentiating into monocytes. Thus, the term "monocytic cell"
includes not
only differentiated monocytes, but also pluripotent stem cell and committed
progenitor
cells which differentiate into monocytes, as well as other effector cells
which terminally
differentiate from monocytes (e.g., macrophages and/or mononuclear phagocytes,
and
the like). These other cells are well-known and have been previously described
(Zhao,
et al., Proc Natl Acad Sci USA, 2003, 100:2426-31, Strauss-Ayali, et al., J
Leukoc Biol,
2007, 82:244-52, Tacke and Randolph, Immunobiology, 2006, 211:609-18, Vega, MA
et
al, Inmunologia 2006, 25(4): 248-272). The term "monocytic cell" also includes
monocyte-derived multipotential cells (MOMC), which can display morphological
and
phenotypic features of endothelial and mesenchymal cells (Seta and Kuwana,
Keio J
Med, 2007, 56:41-47).
The term "polymer" as used herein refers to any monomer or polymer molecular
species that can be polymerized to form a matrix of the invention. As such, a
solution
containing one or more polymers may contain a chemical species comprising one
subunit of a polymer compound (e.g., a monomer) or two or more subunits
covalently
2
WO 2010/060104 PCT/US2009/065797
linked with each other. In some embodiments, a polymer for use in creating
matrix of
the invention will have one or more reactive groups per molecule. In some
embodiments, a polymer may have an essentially linear structure. In some
embodiments, a polymer may have a branched structure, comprising at least one
branch
point from which two or more portions of the polymer molecule originate.
The term "linker" as used herein refers to connections between molecules of
the
polymer network wherein one or molecules is bound or physically associated
with two
or more other molecules of the polymer network simultaneously.
The term "matrix" as used herein refers to a liquid, semi-solid or solid
polymer
substance (e.g., cross-linked polymeric substance) that has the capacity to
comprise
cells. In preferred embodiments, the term "matrix" refers to a biodegradable
hydrogel
that may be in any polymerization state.
The term "hydrogel" as used herein refers to a polymeric substance that
absorbs at
least 90% of its weight in water.
The term "semisolid matrix" as used herein refers to a composition of matter
that
has a rigidity and viscosity intermediate between a solid and a liquid e.g., a
gel.
Biocompatible materials are generally considered to be materials that perform
with an appropriate host response in a specific application, with the
additional quality of
not having toxic or injurious effects on biological systems. The term
"biocompatible" as
used herein refers to the ability of a hydrogel to perform with an appropriate
host
response when delivered as described in the present invention.
The term "liposome" as used herein refers to microscopic vesicles comprising
an
outer lipid layer. In some embodiments, the outer lipid layer is a lipid
bilayer. In other
embodiments, the outer lipid layer of the liposomes described herein is a
lipid
monolayer. In such embodiments where the outer lipid layer is a lipid
monolayer, the
liposomes are also referred to as micelles.
The term "liposome matrix" as used herein refers to a matrix into which
liposomes are embedded.
The term "tumor antigen" as used herein refers to any antigenic material
present
in a tumor cell. A tumor antigen is preferably a polypeptide. In some
embodiments, a
tumor antigen is a polypeptide that is present on the outer surface of a tumor
cell. In
some embodiments, a tumor antigen is expressed at a higher level in a tumor
cell than in
a normal, non-tumorigenic cell. In other embodiments, a tumor antigen is
expressed in a
3
WO 2010/060104 PCT/US2009/065797
tumor cell and is not expressed in a normal cell. A tumor antigen, or a
mixture of tumor
antigens, may be obtained from a tumor cell or a tumor tissue, e.g., tissue
from a tumor
biopsy. A tumor antigen can also be produced recombinantly. In some
embodiments, a
tumor antigen is purified from a tumor cell or a tumor tissue extract. In
other
embodiments, a tumor antigen is used in the compositions and methods of the
invention
without purification. A tumor antigen may be obtained from a tumor in a
subject,
encapsulated in liposomes embedded within a liposome matrix, and implanted
into the
same subject, in accordance with the methods of the invention. A tumor antigen
may
also be obtained from other sources. Accordingly, a tumor antigen used in the
compositions and methods described herein can be allogeneic or syngeneic with
respect
to a subject to whom the tumor antigens are administered as part of a liposome
matrix.
II. Liposomes
Aspects of the invention include one or more liposomes carrying one or more
compounds such as a small molecule, a protein, a polypeptide, DNA, RNA or
other
genetic material such as an siRNA, a small molecule, a drug or a chemical
composition.
Liposomes are microscopic vesicles comprising an outer lipid layer. In some
embodiments, the outer lipid layer is a lipid bilayer. In other embodiments,
the outer
lipid layer of the liposomes described herein is a lipid monolayer. In such
embodiments
where the outer lipid layer is a lipid monolayer, the liposomes are also
referred to as
micelles lReagents suitable for producing liposomes include, but are not
limited to, a
phospholipid such as distearoyl-phosphatidylglycerol (DSPG), 1,2-distearoyl-sn-
glycero-3-phosphocholine (DSPC), dioleoyl phosphatidyl choline (DOPC),
dioleoyl
phosphatidylglycerol (DOPG), phosphatidylglycerol (PC), phosphatidic acid
(PA),
and/or phosphatidylglycerol (PG). The saturated lipids, including but not
limited to
Dimyristoylphosphatidylcholine (DMPC), dipalmitoyl phosphatidylcholine (DPPC),
dipalmitoyl phosphatidic acid (DPPA), and dipalmitoyl phosphatidylglycerol
(DMPG)
can also be used in liposome production. In some embodiments, stearylamine can
be
used when cationic liposomes are preferred, and natural acidic lipids, such as
phosphatidylserine (PS), PG, phosphatidylinositol (PI), PA, and cardiolipin
(CL) can be
added when anionic liposomes are desired. In some embodiments, cholesterol can
be
included to stabilize a liposome bilayer. Small amounts of antioxidants,
including but
4
WO 2010/060104 PCT/US2009/065797
not limited to a-tocopherol or 0-hydroxytoluidine (BHT), can be included when
polyunsaturated neutral lipids are used.
The core of the liposome is aqueous and can be used to hold different
compounds such as small molecules, drugs, polypeptides, or genetic material
(DNA,
RNA, cDNA, siRNA). Hydrophilic compounds can be trapped inside the liposome,
while hydrophobic compounds can be carried in the lipid portion of the
liposome.
Liposomes range in size from 20 nanometers to over 1000 nanometers.
Accordingly,
liposomes may be 20 nm, 25 nm, 30 nm, 40 nm, 50 nm, 60 nm, 70 nm, 80 nm, 90
nm,
100 nm, 150 nm, 200 nm, 250 nm, 300 nm, 350 nm, 400 nm, 450 nm, 500 nm, 550
nm,
600 nm, 650 nm, 700 nm, 750 nm, 800 nm, 850 nm, 950 nm, or 100 nm. In
exemplary
embodiments, the liposomes range from 100 nm to 200 nm. The size of the
liposomes
can be cotroled by methods such as sonication and filteration. Liposomes are
diverse and
can be formed in different sizes and lipid compositions. Additional properties
and
methods of making liposomes are further described in Basu, Subhash C.; Basu,
Manju
(Eds.) Liposome Methods and Protocols, Methods in Molecular Biology, Vol. 199,
(2002); and in Liposome Technology, Third Edition, by Gregory Gregoriadis
(Editor),
Informa HealthCare, (September 12, 2006), the entire contents of which are
incorporated
herein by reference in their entirety.
Different types of liposomes include Sterically Protected Liposomes such as
PEGylated liposome. Liposomes can optionally be surface modified liposomes,
such as
liposomes in which proteins have been incorporated at the surface for
interaction with
cells. Such proteins include, but are not limited to, antibodies, peptides,
receptors, and
other proteins having the capacity to interact with cell-surface receptors.
Binding of
proteins and peptides to liposomes may be accomplished through amino acid
groups or
through sulfhydryl groups. Carbohydrates and other small molecules may
likewise be
bound to the liposomal surface. Liposome modifications can be used in order to
target
specific cells by, for example, incorporating specific ligand that will bind
to a specific
cell receptor. Surface modification can also be used to attach the liposome to
the matrix.
Liposomes can optionally be produced to carry positive or negative charge. The
charge
of the liposome can be used in order to keep the liposome in the matrix. For
example,
positively charged liposomes will be attracted to a negatively charged matrix.
The
combination of liposome size versus matrix pore size and liposome electrical
charge can
be used to maintain the liposomes in the matrix.
5
WO 2010/060104 PCT/US2009/065797
III. Matrix Compositions
The present invention features liposomes embedded in certain matrices for
delivery to target sites (e.g., at desired sites of injection, implantation,
and the like). A
matrix of the invention can include activating and/or polarizing agents as
described
herein for the purpose of activating, further activating, polarizing, further
polarizing
and/or maintaining the activation or polarization state of infiltrating
monocytic cells.
Aspects of the invention include one or more hydrogels, which may comprise
polylactic acid, polyglycolic acid, other polyhydroxy acids, copolymers of two
or more
polyhydroxy acids, polyorthoesters, polyanhydrides, polycaprolactone, gelatin,
collagen,
cellulose, derivatized cellulose, chitosan, alginate, thiol-modified
hyaluronan, and/or
combinations thereof. In some embodiments, a cross-linking agent is comprised
by a kit
of the invention and may comprise glutaraldehyde, diphenylphosphoryl azide,
transglutaminase, dimethyl suberimidate, self assembling proteins or peptides,
DMS-
treated collagen, dimethyl 3,3'-dithiobispropionimidate, multivalent ions,
calcium ions,
N,N methylene-bisacrylamide (MBA), acrylamide, allyl methacrylate, ethylene
glycol
dimethacrylate, and tripolyphosphate.
The matrix used with embodiments of the invention can be a biocompatible
matrix suitable for implanting in contact adjacent to, or at the site of, the
target tissue or
at a site where localized recruitment of phagocytic cells, e.g., monocytes is
therapeutically desired. Preferably, the matrix is a biodegradable material,
such as a
synthetic polymer degrading by hydrolysis, for example, polyhydroxy acids like
polylactic acid, polyglycolic acid and copolymers thereof, polyorthoesters,
polyanhydrides, proteins such as gelatin and collagen, or carbohydrates or
polysaccharides such as cellulose and derivatized celluloses, chitosan,
alginate, thiol-
modified hyaluronan or combinations thereof, so that over the course of
several days or
weeks after implantation of the matrix material, the matrix gradually
disappears. In a
preferred embodiment, the matrix is a hydrogel, defined as a matrix wherein
typically
approximately 90% by weight of the matrix is absorbed with water. Other
hydrogels for
use with embodiments of the invention can be formed by ionic or covalent cross
linking
of a variety of water soluble polymers such as polyphosphazenes,
polysaccharides such
as alginate, and proteins such as gelatin.
In certain embodiments, the hydrogel material will be capable of forming a
semi-
solid matrix on its own. One example of such a hydrogel material is liquid
collagen in
6
WO 2010/060104 PCT/US2009/065797
physiologic pH which converts to a semisolid state upon exposure to body
temperature.
In other embodiments, when the hydrogel material cannot on its own form a
semisolid
matrix or produce the desired physical properties, the matrix will further
comprise a
cross-linking agent which will form the semisolid matrix with the hydrogel
material.
Examples of cross-linking agents useful in the matrix of this invention
include, but are
not limited to, glutaraldehyde, diphenylphosphoryl azide, transglutaminase,
dimethyl
suberimidate, DMS-treated collagen, dimethyl 3,3'-dithiobispropionimidate,
multivalent
ions, calcium ions, N,N methylene-bisacrylamide (MBA), acrylamide, allyl
methacrylate, ethylene glycol dimethacrylate, and tripolyphosphate.
In certain embodiments, the matrix is biodegradable through hydrolysis of the
hydrogel polymer. The stability of the matrix to degradation can be altered
through the
use of different hydrogel materials, different cross-linking agents and
combinations
thereof. The desired stability of the matrices of this invention ranges from
several days
to several weeks, depending upon the disease or condition to be treated by the
matrix.
In some embodiments, the hydrogel material and/or the matrix will initially be
in a
liquid state and then converted to a semisolid state through one or more of
the following:
change in pH, the addition of copolymer(s), irradiation, temperature change,
the addition
of a catalyzer, or the addition of a cross linker. Such liquid compositions
are also part
of the present invention.
In both a liquid state and in the final semi-solid state, the matrix of this
invention
is injectable into a patient at the site of desired treatment. Thus, according
to one
embodiment, the invention provides an injectable composition comprising:
a. a hydrogel; and
b. liposomes containing a desired product, wherein the composition is in or
is convertible to a semisolid state.
Polymer consistency in the matrix can be manipulated to produce soft or hard
matrices for different delivery methods such as injection or implantation.
According to some embodiments, the matrix may additionally comprise an
insoluble, hydratable biocompatible polymer scaffold, such as Gelfoam . In
these
embodiments, the liposomes are typically adhered to the scaffold and then the
scaffold
containing the adhered liposomes is surrounded by the semisolid hydrogel (and
optionally a cross-linker).
7
WO 2010/060104 PCT/US2009/065797
A matrix of the invention may be formulated with a variety of different
polymer
ingredients and polymers in different states in order to achieve desired
attributes in the
matrix. For example, in some embodiments of the invention, solid collagen or
gelatin
particles or granules are mixed with liquid collagen before introduction of
liposomes and
delivery to an organism. This is done to create a matrix with a reduced
tendency for
dispersion than a matrix formed with liquid collagen alone. In some
embodiments, a
matrix can be formulated with a combination of polymers of different types
and/or
different physical states to create a matrix with particular dimensions or
attributes upon
delivery. Matrices of the invention may be formulated with a particular
polymer or a
particular combination of polymers (of different molecular formulas and/or
physical
states) to enhance cohesion of the matrix upon delivery and/or to reduce
immersion of
the matrix into tissues, fibers, internal spaces or other structures or voids
within the
organism. In some embodiments, use of a particular polymer or a particular
combination of polymers used to formulate a matrix creates a matrix upon
delivery that
has a reduced surface area in relation to volume as compared to a matrix
formulated with
one kind of polymer alone. In certain embodiments, a matrix with a reduced
surface
area to volume ratio can have a more spherical shape.
The semisolid hydrogel matrix can be injected via a syringe or implanted
during
a surgical procedure. Depending on the specific indication, the matrix is
designed to
degrade in 1 to 180 days. Depending on the specific indication, the matrix may
contain
chemoattractants to attract specific cell types.
IV. Modulation of Monocyte Behavior Using Liposome Embedded Matrix
Monocytes are a type of leukocyte, or white blood cell, which have an integral
role in the innate immune system. Following the appearance of signals
delivered from a
specific site in the body, monocytes are mobilized by chemotactic signals and
adhere to
the activated endothelium through interactions mediated by adhesion molecules
including P-CAM, V-CAM and I-CAM on endothelial cells and CD18 and CD11B on
monocytes. Following their adhesion to the endothelium, monocytes transmigrate
into
the tissue and differentiate into macrophages.
Together with neutrophils, eosinophils and natural killer cells, monocytes
function as a first-line defense to detect, eliminate or contain invading
microbes and
toxic macromolecules. Monocytes responses towards these targets are rapid and
8
WO 2010/060104 PCT/US2009/065797
triggered by structures, commonly referred to as Pathogen-Associated Molecular
Patterns (PAMP). Whenever the innate immunity is unable to handle an invading
microorganism, monocytes function as effector cells of the adaptive immune
system,
after receiving the appropriate activation and information from antigen-
specific T and B-
lymphocytes.
Monocytes have also essential functions in wound healing and resolution of
inflammation, mediating cell migration, extra-cellular matrix remodeling and
angiogenesis, all of which are required for tissue repair.
Consequently, an ultimate goal of monocytes is the maintenance of tissue
homeostasis and integrity. This is achieved by various monocyte functions,
such as,
secretion of specific proteins, scavenging, elimination of pathogen and tumor
cells,
clearance of senescent cells, control of tissue cell growth and modulation of
the extra-
cellular milieu.
To accomplish these tasks, monocytes exhibit a highly flexible gene expression
program that allows them to adapt and respond to changes in their surrounding
micro-
environment, as well as to recruit, engage and coordinate other cell types in
restoring
normal tissue structure and function. These various monocyte activities are
not
displayed concomitantly and, in fact, some of these activities are clearly
contradictory
(e.g., degradation versus synthesis of extracellular matrix). Thus, tissue
monocytes are
functionally heterogeneous under basal conditions, and exhibit a large degree
of
variability upon activation by endogenous factors or exogenous stimuli (see
Vega, MA
et al, Inmunologia 2006, 25(4): 248-272).
Monocyte implantation at site of ischemic tissue has been attempted as a
therapeutic approach for the treatment of various conditions such as cancer,
heart
disease, ischemia, nerve injury, wound healing and diabetes. Similarly,
monocyte
therapy has been used for the delivery of therapeutic proteins by genetic
manipulation,
activation or transformation of the monocytes (Muhlebach, M.D., et al., Mol
Ther, 2005.
12:1206-16; Lu, Y., et al., Cell Mol Biol, 2003. 49:1151-6; Spiekermann, K.,
et al., Eur J
Haematol, 2001. 67:63-71; US 2006/0257359). The use of monocytes has also been
described for nerve repair and spinal cord injury treatment (Lazarov-Spiegler,
0.,
Solomon, A.S., and Schwartz, M. Glia, 1998. 24:329-37; Rapalino, 0., et al.,
Nat Med,
1998. 4:814-21; Schwartz, M., et al., Neurosurgery, 1999. 44:1041-6; U.S.
Patent No.
6,267,955).
9
WO 2010/060104 PCT/US2009/065797
While some progress has been made in the field of cellular therapy and
therapeutic protein delivery for tissue repair, there exists a need to improve
the ability to
manipulate monocyte behavior in vivo.
Monocytes have the potential to differentiate and adopt different cell
phenotypes
based on their microenvironment and the molecules to which they are exposed
(Mantovani, A. et al, Trends Immunol 2004, 25: 677-686; Mantovani, A et al,
Immunity
2005, 23:344-346; Mantovani, A et al, Eur J Immunol 2007, 37:14-16; Pinhal-
Enfield, G
et al, Am J Pathol 2003,163:711-721; Zhao, Yet al., Proc Natl Acad Sci USA
2003,
100:2426-2431; Mantovani, A, Blood 2006, 108(2):408-409). In the body,
monocytes
routinely migrate from the blood circulation into different tissues and organs
where they
differentiate into resident macrophages and spend the majority of their life
span.
In various embodiments, the present invention is based on the development of
compositions and methods for delivery of compounds encapsulated in liposomes.
Embodiments of the invention feature liquid, semi-solid and solid matrices
containing
embedded liposomes, and methods for their formation and use. Through
phagocytosis,
monocytes infiltrating the matrix selectively incorporate the liposomes and
their
contents. The matrices may be injectable or implantable.
In exemplary embodiments, liposomes are introduced to a matrix (hydrogel) and
are embedded in the matrix. The matrix can include one or more agents for
recruiting
cells (e.g., monocytes) to the matrix. Liposomes may be incubated with agents
before
being contacted with a matrix of the invention in some embodiments. In some
embodiments, a matrix of the invention is formulated to incorporate agents and
compounds that exert one or more effects upon cells which infiltrate the
matrix. In other
embodiments, a matrix of the invention is formulated to incorporate agents and
compounds that attract cells (e.g., monocytes) to the matrix. In additional
embodiments,
the matrix is permeable to compounds produced by infiltrating cells. Compounds
produced or secreted by cells within a matrix may diffuse out of the matrix
and create
effects in the surrounding environment in some embodiments. Additional
embodiments
of the invention include kits comprising a matrix of the invention and
instructions for
practicing the invention. In some embodiments, a kit of the invention includes
matrix
and one or more reagents for preparing liposomes for incorporation therein.
One embodiment of the invention features an implantable, semi-solid matrix
comprising a hydrogel material and liposomes embedded therein. In particular
WO 2010/060104 PCT/US2009/065797
embodiments, the matrix contains one or more agents useful in recruiting
cells, e.g.,
monocytic cells, to a site of implantation. In other embodiments, the
liposomes
embedded in the matrix contain one or more agents which modify or modulate a
behavior of monocytic cells. The behavior modified or modulated in this manner
includes, but is not limited to, secretion of products produced by monocytic
cells.
The behavior or phenotype of monocytes may be modulated to achieve a
particular
therapeutic result.
For example, modulating the behavior or phenotype of monocytes at a specific
location within a tissue can be used to deliver therapeutic proteins secreted
from
monocytes to the tissue. In one embodiment, this approach may be used to
induce
angiogenesis. Tissues and body parts can become damaged for a variety of
different
reasons. These include, but are not limited to a chronic disease such as
autoimmune
disorders, diabetes or atherosclerosis, or an acute event such as injury,
trauma or an
occlusive vascular event resulting in tissue injury due to ischemia. All of
these
conditions may result in loss of tissue function. Regeneration of injured or
lost tissue
can be achieved by several means, including replacing the damaged tissue with
healthy
tissue (such as by surgical tissue flap), by delivering stem cells or
progenitor cells that
will differentiate into new functional tissue, by enhancing circulation
through the growth
of new blood vessels in the tissue, and/or by mobilization of cells, oxygen
and nutrients
to the tissue thereby enhancing its regeneration. In order to facilitate
regeneration, it is
desirable to recruit cells within a patient's body to perform in a manner that
will enhance
regeneration of a damaged tissue or act to heal a damaged tissue. Such
treatment can be
achieved, for example, by manipulating cells in a specific location to act
towards the
growth of new blood vessels by secreting angiogenic factors, including but not
limited to
vascular endothelial growth factor. In another embodiment the invention can be
used to
differentiate stem cells or progenitor cells to specific cell types in a
specific location in
the body in order to regenerate tissue function.
In another embodiment, modulating the behavior or phenotype of monocytes at a
specific location within a tissue can be used to trigger an immune response
against an
antigen presented by dendritic cells that differentiated from monocytes.
Monocytes may
differentiate into antigen-presenting dendritic cells upon exposure to antigen
and/or
exposure to factors that induce differentiation to a dendritic phenotype. In
preferred
embodiments, the antigen is a tumor antigen. Upon exposure to an antigen,
e.g., a tumor
11
WO 2010/060104 PCT/US2009/065797
antigen, monocytes can differentiate into dendritic cells that display the
antigen on the
cell surface. The dendritic cells can then activate T-cells with which they
come into
contact, triggering a cell-mediated immune response against the antigen. If
the antigen
is a tumor antigen, the cell-mediated immune response is directed against the
antigens
present in a tumor mass, effectively activating an immune response against the
tumor.
Antigens, including tumor antigens, can be delivered to monocytes by
encapsulating the
antigens inside liposomes and embedding them in a matrix, as described herein.
Additional agents or factors can promote differentiation of monocytes to
dendritic cells.
These factors can be presented to monocytes separately or in combination with
an
antigen. In some embodiments, these agents include, but are not limited to,
granulocyte-
macrophage colony- stimulating factor, interleukin-4, TNFa, interleukin-15 and
others.
In some embodiments, these agents are deliverd within the liposomes together
with the
tumor antigens to induce differentiation of monocytes to dendritic cells. In
particular
embodiments, the differentiation agents and the tumor antigens are contained
within the
same liposomes. In other embodiments, the differentiation agents and the tumor
antigens are contained within separate liposomes embedded in the same matrix.
Factors
involved in the differentiation of monocytes to dendritic cells can also be
incorporated
within the hydrogel. Accordingly, in another embodiment, liposomes containing
tumor
antigens can be embedded in a hydrogel matrix containing one or more agents
involved
in differentiation of monocytes to dendritic cells, e.g., granulocyte-
macrophage colony-
stimulating factor, interleukin-4, TNFa, and interleukin-15. Additional
factors involved
in the differentiation of monocytes to dendritic cells are further described
in Sabrina
Mariotti el al, The FASEB Journal. 2008;22:3370-3379, Suresh Kumar, Robert
Jack,
Journal of Endotoxin Research, Vol. 12, No. 5, 278-284 (2006) and S. Nagaraj
et al,
Indian J Med Res 119, April 2004, pp 133-138 incorporated herein by reference
in its
entirety.
In another embodiment, modulating the behavior or phenotype of monocytes at a
specific location within a tissue can be used to deliver therapeutic proteins
secreted from
monocytes to the tissue. The compositions and methods of the invention can be
used to
differentiate stem cells or progenitor cells to specific cell types in a
specific location in
the body in order to regenerate tissue function. For example, the compositions
and
methods of the invention can be used to change a cell from one type to another
12
WO 2010/060104 PCT/US2009/065797
(reprogramming) in order to overcome a shortage in specific cells, such as
insulin-
secreting beta cells.
Monocytes may be isolated from an individual and manipulated in vitro to
achieve a desired phenotype. Such monocytes can then be delivered to a tissue
by
injection. Alternatively, if localization of delivery is desired, monocytes
can by
delivered by embedding them within a biocompatible matrix such as collagen or
hyaluronic acid. In both instances autologous or allogeneic monocytes can be
used.
Alternatively, endogenous monocytes can be manipulated to concentrate in
specific locations in the body. As monocytes by nature of their function
invade foreign
objects, delivery of a foreign object in the form of a matrix (e.g., a matrix
comprising
collagen) will result in monocyte infiltration. The tendency of monocytes to
infiltrate
matrices in vivo can be used in order to differentiate these monocytes within
the matrix
by loading the matrix with specific molecules that direct the specific
differentiation of
monocytes. This method offers the advantage of using endogenous cells,
eliminating the
risk of immune response towards foreign cells and avoiding the need to draw
blood and
achieve differentiation in vitro.
In order to allow the differentiation of endogenous monocytes in the delivered
matrix, the matrix should be loaded with compounds which stimulate or promote
differentiation. Unless the compounds used for monocyte differentiation are
coupled to,
or embedded in the matrix material they will freely difuse from the matrix and
disperse
in the tissue in which the matrix is embedded, resulting in a rapid decline in
the
concentration of the compounds within the matrix.
Monocytes are phagocytic cells, which use phagocytosis as means for
incorporating foreign objects, bacteria and debris. Monocyte phagocytosis is
used in
order to deliver compounds and drugs to monocytes by encapsulating the
delivered
compound in a liposome and injecting the liposome suspension into the blood
circulation. Through phagocytosis, monocytes selectively incorporate the
liposomes and
their content. Monocytes can be selectively targeted over other leucocytes by
manipulating liposome size. Optimal liposome sizes for targeting monocytes
range
between, e.g., 20 nm and 1000 nm, 20 nm and 900 nm, 20 nm and 800 nm, 20 nm
and
700 nm, 20 nm and 600 nm, 20 nm and 500 nm, or 25 nm and 400 nm. In preferred
embodiments, optimal liposome size ranges between 50 nm and 300 nm, more
13
WO 2010/060104 PCT/US2009/065797
preferably between 75 nm and 250 nm, and most preferably between 100 nm and
200
nm.
By incorporating liposomes containing specific compounds inside a semisolid
matrix comprising a hydrogel material such as collagen or hyaluronic acid it
is possible
to achieve local delivery of liposomes to cells to control the cells'
behavior.
Accordingly, the use of liposomes embedded in a semisolid matrix is an
advantageous
means of achieving specific delivery of desired compounds to phagocitic cells
such as
monocytes and macrophages as well other endogenous cell derived from monocytes
such as dendritic cells. Neutrophils can also phagocytose liposomes, but
mainly
participate in phagocytosis of antibody and complement coated antigens.
Monocytes
that invade a liposome-embedded semisolid matrix encounter liposomes and
incorporate
the liposome contents through phagocytosis. The liposomes hold desired
compounds
within the matrix, reducing the diffusion of the compounds from the matrix to
the tissue.
The specific phagocytic nature of monocytes will typically result in specific
delivery to
monocytes, although neutrophils may also perform phagocytosis but mainly of
antibody
and complement coated antigens. Liposomes can be targeted to monocytes and
macrophages by making the liposome size range between 100 nm and 200 nm,
although
monocytes can phagocyte smaller as well as larger liposomes as well, e.g.,
liposomes
between 25 nm and 400 nm.
As there is no diffusion of compounds from liposomes, the amount or dosage of
compounds within the liposomes, and consequently within the tissue into which
the
liposome matrix is introduced, will remain constant. A common problem of
matrix
based delivery systems is the diffusion of compounds embedded in the matrix
into the
surrounding tissue, changing the concentration of the compound in the matrix
and
affecting its bioactivity. Contents contained within liposomes will be trapped
within the
liposomes and, consequently, trapped within the matrix, thereby allowing the
contents to
interact only with phagocytic cells, e.g., monocytes, infiltrating the matrix.
When a desired compound is embedded within the matrix, any cell having
contact with the matrix is affected by the compound. The contents of liposomes
are
typically available only to phagocytic cells such as monocytes. However,
liposomes can
be targeted to other cells by specific targeting molecules such as antibodies
or peptides
placed on the liposome surface, thereby allowing the contents of the liposomes
to be
14
WO 2010/060104 PCT/US2009/065797
specifically targeted to particular cell types, minimizing the effect of the
contents on
cells not targeted for treatment.
This method will allow the differentiation of endogenous monocytes into
different phenotypes or to reprogramming to different functional cells based
on the
desired function and therapeutic outcome.
V. Induction of an An2io2enic Phenotype
Control over the behavior of cells in a specific location in the body can be
used
for the treatment of different indications such as ischemia where a tissue is
suffering
from insufficient circulation resulting in cell being starved or in low supply
of oxygen.
As a result of this condition, cells may lose function or die. Increasing the
production of
angiogenic signals within the ischemic tissue that promote growth of blood
vessels can
help increase local circulation, help regenerate the tissue, and decrease
ischemia. To
achieve this goal one embodiment of the present invention describes materials
and
methods for the creation of a hydrogel embedded with liposomes that carry a
bioactive
compound that changes cellular behavior. By delivering the liposome embedded
hydrogel to the ischemic tissue, monocytic cells that infiltrate the matrix
incorporate the
matrix embedded liposome containing the bioactive material and as result act
to promote
angiogenesis.
The methods and compositions of the invention may be used to induce an
angiogenic phenotype in monocytes. This can be used to treat limb ischemia,
wound
healing, and other conditions associated with poor circulation. For example, a
liposome
matrix containing molecules that induce an angiogenic phenotype in monocytes
can be
delivered to a muscle tissue, or to connective tissues, internal organs, and
spaces
between tissues. Induction of an angiogenic phenotype in monocytes may be
achieved
by implanting in a tissue a permeable semisolid matrix embedded with liposomes
containing adenosine (a trigger for monocyte differentiation into the
angiogenic
phenotype). Matrix infiltrating monocytes will adopt an angiogenic phenotype
and will
secrete vascular growth factors to promote the creation of new blood vessels
and
improve the circulation of the surrounding tissue.
The present invention features methods and compositions for endogenous cell
therapy which employ an implantable matrix embedded with liposomes. Through
phagocytosis, monocytic cells, e.g. monocytes, infiltrating the matrix
selectively
WO 2010/060104 PCT/US2009/065797
incorporate the liposomes and their contents. Accordingly, by incorporating
liposomes
containing specific compounds inside an implantable matrix, it is possible to
deliver
compounds to monocytes and modulate monocyte behavior.
In one aspect, the invention provides an implantable, semisolid matrix
comprising a hydrogel material and liposomes embedded therein, wherein the
liposomes
contain at least one bioactive material, and wherein the matrix is permeable
to the
infiltration of cells from an implantation environment and to products
secreted from the
cells into the environment. In one embodiment of this aspect, the bioactive
material is
selected from the group consisting of a protein, a peptide, a nucleotide, a
DNA, a RNA,
a siRNA, and a cDNA, or a combination thereof. In another embodiment, the
bioactive
material is a small molecule, a drug or a combination thereof. In another
embodiment,
the liposomes contain more than one bioactive material. In an exemplary
embodiment,
the more than one bioactive materials include a biological and a chemical
material.
In another embodiment of this aspect, the liposomes carry the material in the
liposomal hydrophilic core, in the membrane on its surface or in a combination
thereof.
In yet another embodiment, the hydrogel contains a biological or chemical
compound
that is not carried within the liposomes. In one embodiment, the biological or
chemical
compound is a chemoattractant protein. In another embodiment, the
chemoattractant
protein is monocyte chemotactic protein-1.
In one embodiment, the liposomes are attached to the hydrogel matrix by a
chemical bond, e.g., a peptide bond or an ionic bond. In another embodiment,
the
hydrogel material contain cells added to the hydrogel material prior to its
implantation in
the body. In one embodiment, the cells are monocytes.
In another embodiment, the hydrogel of the matrix comprises copolymers of two
or more polyhydroxy acids, polyorthoesters, polyanhydrides, gelatin, collagen,
cellulose,
derivatized cellulose, chitosan, alginate, hyaluronan, thiol-modified
hyaluronan, and
combinations or copolymers thereof. In one embodiment, the polyhydroxy acid is
polylactic acid, polyglycolic acid or other polyhydroxy acid.
In one embodiment, the matrix further comprises a cross-linking agent. In one
embodiment, the cross-linking agent is glutaraldehyde, diphenylphosphoryl
azide,
transglutaminase, dimethyl suberimidate, DMS-treated collagen, dimethyl 3,3'-
dithiobispropionimidate, multivalent ions, calcium ions, N,N methylene-
bisacrylamide
16
WO 2010/060104 PCT/US2009/065797
(MBA), acrylamide, allyl methacrylate, ethylene glycol dimethacrylate, or
tripolyphosphate, or combinations thereof.
In another aspect, the invention features a method for programming an
implantable, semisolid matrix comprising a hydrogel material and liposomes
embedded
therein to affect the behavior of cell, comprising formulating within the
liposomes a
compound capable of affecting the cell's behavior, such that the cell
infiltrates the
semisolid matrix comprising the hydrogel material and takes up the liposomes
through
phagocytosis or through fusion of the liposome membrane with the cell
membrane.
In another aspect, the invention features a method for affecting the behavior
of a
cell at or near a site of implantation in a subject, comprising implanting at
the site an
implantable, semisolid matrix comprising a hydrogel material and liposomes
embedded
therein, wherein the liposomes comprise at least one compound capable of
affecting the
cell's behavior, such that the cell infiltrates the semisolid matrix
comprising the
hydrogel material and takes up the liposomes through phagocytosis or through
fusion of
the liposome membrane with the cell membrane. In various embodiments, the
behavior
is an angiogenic activity, an immunosuppressive activity, or an inflammatory
activity.
In certain embodiments, the cell is a monocytic cell, e.g., a monocyte or a
macrophage.
In an exemplary embodiment, the monocytic cell secretes vascular growth
factors at or
near the implantation site. In exemplary embodiments, the compound contained
within
the liposomes is adenosine, IL-4, IL-10, or combinations thereof. In other
embodiments,
the compound contained within the liposomes is IL-10, IL-4, IL-13, an IL-1
receptor
ligand, PGE2, TGF-(3, TNFa, lactic acid, lipoteichoic acid, NADH dehydrogenase
5,
subunit 1, poly (adenosine diphosphate-ribose) polymerase, pyruvate, Colony
Stimulating Factor-1, adenosine, an adenosine analogue, NECA, LPS, Pam3CSK4,
E.
coli LPS, R848, imiquimod, non-methylated CpG DNA, ODN2006, thioredoxin
peroxidase, Trapidil, TLR2 agonist (e.g., Pam3CysSerLys4, peptidoglycan (Ppg),
PamCys), a TLR3 agonist (e.g., IPH 31XX), a TLR4 agonist (e.g., Aminoalkyl
glucosaminide phosphates [AGPs], E6020, CRX-675, 5D24.D4, RC-527), a TLR7
agonist (e.g., Imiquimod, 3M-003, Aldara, 852A, R850, R848, CL097), a TLR8
agonist
(3M-002), a TLR9 agonist (Flagellin, Vaxlmmune, CpG ODN (AVE0675, HYB2093),
CYTO05- 15 A11QbG10, dSLIM), adenosine Al agonists (R-PIA, CPA TCPA, CVT-
3146, CVT-510, GR 79236, WAG 994), adenosine A2 agonists (CGS 21680, APEC,
17
WO 2010/060104 PCT/US2009/065797
2HE-NECA), and/or adenosine A3 agonists (e.g., IB-MECA, CI-IB-MECA, 3'-
Aminoadeno sine- 5'-uronamides) and Alendronate, and combinations thereof.
In another aspect, the invention features a method for delivering a secreted
product to a localized site in a subject comprising, providing at the
localized site a
liposome matrix composition described herein, and maintaining the matrix or
composition at the localized site for a period of time sufficient for the
secreted product
to interact with the localized site. In one embodiment, the implantation site
is within an
ischemic tissue.
Additional embodiments of the invention feature an injectable composition
comprising a hydrogel material and liposomes that are added to the injectable
composition, where the liposomes include one or more agents which modify or
modulate
a behavior of monocytic cells. Such agents include, but are not limited to,
nucleic acid
molecules, polypeptides, and small molecule chemical compounds. In some
embodiments, the material is a nucleotide, an expression vector, a cytokine,
or a growth
factor. In exemplary embodiments, the liposomes include one or more of the
following:
IL-10, IL-4, IL-13, an IL-1 receptor ligand, PGE2, TGF-(3, TNFa, INFy, lactic
acid,
lipoteichoic acid, NADH dehydrogenase 5, subunit 1, poly (adenosine
diphosphate-
ribose) polymerase, pyruvate, Colony Stimulating Factor-1, adenosine, an
adenosine
analogue, NECA, LPS, Pam3CSK4, E. coli LPS, R848, imiquimod, non-methylated
CpG DNA, ODN2006, thioredoxin peroxidase, Trapidil, TLR2 agonist (e.g.,
Pam3CysSerLys4, peptidoglycan (Ppg), PamCys), a TLR3 agonist (e.g., IPH 31XX),
a
TLR4 agonist (e.g., Aminoalkyl glucosaminide phosphates [AGPs], E6020, CRX-
675,
5D24.D4, RC-527), a TLR7 agonist (e.g., Imiquimod, 3M-003, Aldara, 852A, R850,
R848, CL097), a TLR8 agonist (3M-002), a TLR9 agonist (Flagellin, Vaxlmmune,
CpG
ODN (AVE0675, HYB2093), CYTO05- 15 A11QbG10, dSLIM), adenosine Al agonists
(R-PIA, CPA TCPA, CVT-3146, CVT-510, GR 79236, WAG 994), adenosine A2
agonists (CGS 21680, APEC, 2HE-NECA), and/or adenosine A3 agonists (e.g., IB-
MECA, CI-IB-MECA, 3'-Aminoadenosine-5'-uronamides), and Alendronate. The
injectable composition is convertible to a semi-solid state in some
embodiments, and the
injectable composition can be permeable to a product secreted by monocytic
cells that
infiltrate the composition. Some embodiments feature injectable compositions
that can
be converted to a semi-solid state by exposing the composition to heat,
ionizing
radiation or ultraviolet radiation. In some embodiments, infiltrating
monocytic cells are
18
WO 2010/060104 PCT/US2009/065797
capable of producing more than one product. In some embodiments, the product
secreted is determined by the content of liposomes embedded within the
injectible
composition. In some embodiments, a product secreted by a monocytic cell is an
angiogenic factor. Vascular endothelial growth factor (VEGF), fibroblast
growth factor
(FGF), platelet derived growth factor (PDGF), hepatocyte growth factor/scatter
factor
(HGF/SF), epidermal growth factor (EGF), and/or Interleukin-8 (IL-8) are
secreted by a
monocytic cell in some embodiments. A product secreted by a monocytic cell may
be
an immunosuppressive factor in some embodiments. A monocytic cell in some
embodiments may secrete one or more immunosuppressive factors such as IL-4, IL-
10
and/or TGF-(3. In some embodiments, a monocytic cell may be a monocyte
precursor
cell and may be a bone marrow cell and/or a monocyte progenitor cell in some
embodiments.
Aspects of the invention include a matrix comprising a hydrogel which may
comprise one or more polymers. In some embodiments, the hydrogel comprises
polylactic acid, polyglycolic acid, other polyhydroxy acids, copolymers of two
or more
polyhydroxy acids, polyorthoesters, polyanhydrides, gelatin, collagen,
cellulose,
derivatized cellulose, chitosan, alginate, thiol-modified hyaluronan, and/or
combinations
or copolymers thereof.
Cross-linkers are comprised by a matrix of the invention in some embodiments.
In particular embodiments, a matrix of the invention comprises one or more of
glutaraldehyde, diphenylphosphoryl azide, transglutaminase, dimethyl
suberimidate,
DMS-treated collagen, dimethyl 3,3'-dithiobispropionimidate, multivalent ions,
calcium
ions, N,N methylene-bisacrylamide (MBA), acrylamide, allyl methacrylate,
ethylene
glycol dimethacrylate, tripolyphosphate, and combinations thereof.
Additional aspects of the invention include methods for recruiting cells
(e.g.,
monocytes) to a localized site in a subject. In some embodiments, a method of
the
invention includes delivering a matrix containing liposomes (i.e., a liposome
matrix) to a
localized site and maintaining the matrix in the localized site for a period
of time
sufficient for cells, e.g., monocytes, to migrate to and/or infiltrate the
localized site. In
some embodiments of the invention, a subject that receives a matrix of the
invention has
a disease, has a condition and/or is at risk for a disease and/or a condition.
In some
embodiments, the disease and/or condition that a subject has or has a risk for
is coronary
artery disease, peripheral artery disease, limb ischemia, ischemic wound,
ischemic ulcer,
19
WO 2010/060104 PCT/US2009/065797
ischemic bowel disease, atherosclerotic ischemic disease, muscle flaps, skin
flaps, organ
transplant, nasolabial folds, wrinkles, conditions which result in scar
formation,
conditions requiring plastic surgery and/or conditions requiring a cosmetic
procedure.
Some aspects of the invention feature a method for treating a subject that has
or
is at risk of having ischemia. In some embodiments, a matrix or composition of
the
invention is administered at a site of ischemia. In some embodiments, the
administration
of a matrix or composition results in recruitment of cells capable of
secreting one or
more angiogenic factors at the site for a time sufficient to prevent or lessen
the effects of
a perfusion injury associated with the ischemia. In some embodiments, a method
for
treating a subject that has or is at risk for cardiac ischemia is featured. In
some
embodiments, the method for administering the liposome matrix to a site is by
injection.
Additional aspects of the invention include methods for reducing the
nasolabial
folds or wrinkles in a subject, comprising administering at the site of the
nasolabial folds
or wrinkles a matrix or composition of the invention, such that secretion of
an
angiogenic factor is effected for a time sufficient to detectably reduce the
number and/or
depth of the nasolabial folds or wrinkles. In some embodiments, a method for
reducing
the nasolabial folds or wrinkles in a subject comprises injecting a matrix or
composition
of the invention.
In some aspects of the invention, a method for reducing an immune response at
a
localized site in a subject is featured, wherein a matrix or composition of
the invention is
administered at a site and cells are recruited that are capable of secreting
one or more
immunosuppressive factors for a time sufficient to detectably reduce the
immune
response at the localized site. In some embodiments, a liposome-containing
matrix or
composition of the invention administered to reduce an immune response at a
localized
site in a subject is injected.
VI. Induction of an immune response against cancer cells
A basic mechanism for fighting cancer cell growth in the body is the ability
of
the immune system to recognize the changes in cells that act in an abnormal
manner and
remove them. Rarely, the immune system fails to recognize a cancer cell as a
problem,
leading to the proliferation of the cancer cell and the development of a
tumor. One
strategy to fight such tumors is to help teach the immune system to recognize
the tumor
as a problem. To achieve this, target antigens from the tumor, from a similar
tumor, or
WO 2010/060104 PCT/US2009/065797
from synthetic peptids are presented to dendritic cells which in turn can
elicit T cell-
mediated tumor destruction. In one embodiment of the present invention, cancer
antigens are encapsulated within liposomes alone or together with other
bioactive
materials such as an adjuvant. The liposomes are embedded within a hydrogel
and
placed in the area of the tumor by injection or implantation. Monocytes that
infiltrate
the matrix incorporate the liposomes by phagocytosis or by fusion of the
liposomes with
the monocytes membrane. The monocytes differentiate into dendritic cells that
elicit a T
cell-mediated response targeting the patients tumor.
The methods and compositions described herein may be used to induce an
immune response against cancer cells. This approach can be used to treat
cancer. In
exemplary embodiments, a hydrogel containing liposomes can be delivered at or
near
the location of a tumor, but can also be delivered to connective tissues,
internal organs,
and spaces between tissues that are not directly in contact with the tumor.
Induction of
an immune response by monocytes may be achieved by implanting in a tissue a
permeable semisolid matrix embedded with liposomes containing cancer antigens
from a
patient or cancer cells or antigens that were produced not from a patient's
cells but can
induce specific reaction against the patient's cancer cells. Matrix
infiltrated monocytes
can differentiate into dendritic cells and can interact with T cells to induce
a cytotoxic
reaction against the cancer cells. The dendritic cells are released from the
matrix
following the degradation of the matrix or by active migration, enabling their
interaction
with T cells and B cells, and the induction of a specific anti cancer immune
response.
The present invention features methods and compositions for endogenous cell
therapy which employ an implantable matrix embedded with liposomes. Through
phagocytosis, monocytic cells, e.g. monocytes, infiltrating the matrix
selectively
incorporate the liposomes and their contents. Accordingly, by incorporating
liposomes
containing specific compounds inside an implantable matrix, it is possible to
deliver
compounds to monocytes and modulate monocyte behavior.
In one aspect, the invention provides an implantable, semisolid matrix
comprising a hydrogel material and liposomes embedded therein, wherein the
liposomes
contain at least one bioactive material, and wherein the matrix is permeable
to the
infiltration of cells from an implantation environment and to products
secreted from the
cells into the environment. In one embodiment of this aspect, the bioactive
material is
selected from the group consisting of a protein, a peptide, a nucleotide, a
DNA, a RNA,
21
WO 2010/060104 PCT/US2009/065797
a siRNA, and a cDNA, or a combination thereof. In another embodiment, the
bioactive
material is a small molecule, a drug or a combination thereof. In another
embodiment,
the liposomes contain more than one bioactive material. In an exemplary
embodiment,
the more than one bioactive materials include a biological and a chemical
material.
In another embodiment of this aspect, the liposomes carry the material in the
liposomal hydrophilic core, in the membrane on its surface or in a combination
thereof.
In yet another embodiment, the hydrogel contains a biological or chemical
compound
that is not carried within the liposomes. In one embodiment, the biological or
chemical
compound is a chemoattractant protein. In another embodiment, the
chemoattractant
protein is monocyte chemotactic protein-1.
In one embodiment, the liposomes are attached to the hydrogel matrix by a
chemical bond, e.g., a peptide bond or an ionic bond. In another embodiment,
the
hydrogel material contain cells added to the hydrogel material prior to its
implantation in
the body. In one embodiment, the cells are monocytes.
In another embodiment, the hydrogel of the matrix comprises copolymers of two
or more polyhydroxy acids, polyorthoesters, polyanhydrides, gelatin, collagen,
cellulose,
derivatized cellulose, chitosan, alginate, hyaluronan, thiol-modified
hyaluronan, and
combinations or copolymers thereof. In one embodiment, the polyhydroxy acid is
polylactic acid, polyglycolic acid or other polyhydroxy acid.
In one embodiment, the matrix further comprises a cross-linking agent. In one
embodiment, the cross-linking agent is glutaraldehyde, diphenylphosphoryl
azide,
transglutaminase, dimethyl suberimidate, DMS-treated collagen, dimethyl 3,3'-
dithiobispropionimidate, multivalent ions, calcium ions, N,N methylene-
bisacrylamide
(MBA), acrylamide, allyl methacrylate, ethylene glycol dimethacrylate, or
tripolyphosphate, or combinations thereof.
In another aspect, the invention features a method for programming an
implantable, semisolid matrix comprising a hydrogel material and liposomes
embedded
therein to affect the behavior of cell, comprising formulating within the
liposomes a
compound capable of affecting the cell's behavior, such that the cell
infiltrates the
semisolid matrix comprising the hydrogel material and takes up the liposomes
through
phagocytosis or through fusion of the liposome membrane with the cell
membrane.
In another aspect, the invention features a method for effecting the behavior
of a
cell at or near a site of implantation in a subject, comprising implanting at
the site an
22
WO 2010/060104 PCT/US2009/065797
implantable, semisolid matrix comprising a hydrogel material and liposomes
embedded
therein, wherein the liposomes comprise at least one compound capable of
affecting the
cell's behavior, such that the cell infiltrates the semisolid matrix
comprising the
hydrogel material and takes up the liposomes through phagocytosis or through
fusion of
the liposome membrane with the cell membrane. In one embodiment of this
aspect, the
behavior is an antigen presenting activity. In an exemplary embodiment, the
cell is a
monocyte, and the compound is a tumor antigen. In one embodiment, the tumor
antigen
is derived from tumor cells or tumor tissue from the subject. In another
embodiment, the
tumor antigen In one embodiment, the monocyte displays a tumor antigen for
recognition by a T cell and/or a B cell at or near the implantation site.
In another aspect, the invention features a method for presenting a tumor
antigen
at a localized site in a subject comprising, providing at the localized site
an implantable,
semisolid matrix comprising a hydrogel material and liposomes embedded
therein,
wherein the liposomes comprise the tumor antigen and maintaining the matrix or
composition at the localized site for a period of time sufficient for a
phagocytic cell to
infiltrate the matrix, phagocytose the antigen and present the antigen to an
immune cell
at the localized site. In one embodiment, the localized site is at or near a
tumor site,
such that an immune response to the tumor is enhanced.
One embodiment of the invention features an implantable, semi-solid matrix
comprising a hydrogel material and liposomes embedded therein. In particular
embodiments, the matrix contains one or more agents useful in recruiting
cells, e.g.,
monocytic cells, to a site of implantation. In other embodiments, the
liposomes
embedded in the matrix contain one or more agents which modify or modulate a
behavior of monocytic cells. The behavior modified or modulated in this manner
includes, but is not limited to, secretion of products produced by monocytic
cells,
antigen presentation by monocytic cells, differentiation into dendritic cells,
and
migration of cells or release of cells from the matrix followed by direct
interaction of the
monocytic cells with other effector cells such as T cells and B cells. One of
the key roles
of monocytes in the immune system is to act as precursors for dendritic cells.
Dendritic
cells are derived from hemopoietic stem cells through either the common
lymphoid or
the common myeloid progenitor pathways. Mo-DC or MDDC refers to dendritic
cells
matured from monocytes. HP-DC refers to dendritic cells derived from
hematopoietic
progenitor cells. Dendritic cells act as antigen presenting cells for other
effector cells of
23
WO 2010/060104 PCT/US2009/065797
the immune system such as T cells. The compositions and methods described
herein can
be used to promote the differentiation of monocytes into dendritic cells. The
dendritic
cells can then be used in cell therapy, including in the treatment of cancer.
Dendritic
cell-based therapy is described in S. Nagaraj et al, Indian J Med Res 119,
April 2004, pp
133-138, and in M Jefford a, E Maraskovsky b, J Cebon c, ID Davis d. The use
of
dendritic cells in cancer therapy. The Lancet Oncology, Volume 2, Issue 6,
Pages 343 -
353, June 2001, the entire contents of which are incorporated herein by
reference.
In exemplary embodiments, liposomes embedded in the hydrogel matrix of the
invention contain one or more tumor antigens. In preferred embodiments, the
tumor
antigens are polypeptide molecules. In other embodiments, the tumor antigens
are
encoded by nucleic acid molecules embedded within the liposomes. The tumor
antigens
may be autologous, allogeneic, or syngeneic. In an exemplary embodiment, the
tumor
antigens are obtained from a tumor sample or biopsy obtained from a patient.
Following
implantation of the liposome matrix in a subject, circulating monocytic cells,
e.g.,
monocytes, will infiltrate the matrix and will phagocytose liposomes
containing the
tumor antigens. In an exemplary embodiment, the subject is the same subject
from
whom the tumor antigens were obtained. After phagocytosis of the liposomes
containing the tumor antigens, the monocytic cells differentiate into
dendritic cells
which activate T-cells in their environment. Activation of T-cells triggers a
cell-
mediated immune response targeted to attack the antigens contained within the
liposomes. If the antigens are tumor antigens, the cell-mediated immune
response is
targeted to attack a tumor containing the tumor antigens. Antigen-presenting
dendritic
cells can also trigger activation of B-cells, stimulating a B-cell response
against a tumor.
In other exemplary embodiments, the liposomes embedded in the hydrogel
matrix of the invention contain one or more agents or factors involved in
differentiation
of monocytes to dendritic cells. In some embodiments, these agents include,
but are not
limited to, granulocyte-macrophage colony-stimulating factor, interleukin-4,
TNFa,
interleukin-15 and others. In some embodiments, these agents are deliverd
within the
liposomes together with the tumor antigens to induce differentiation of
monocytes to
dendritic cells. In particular embodiments, the differentiation agents and the
tumor
antigens are contained within the same liposomes. In other embodiments, the
differentiation agents and the tumor antigens are contained within separate
liposomes
embedded in the same matrix. Factors involved it the differentiation of
monocytes to
24
WO 2010/060104 PCT/US2009/065797
dendritic cells can be incorporated within the hydrogel. Accordingly, in
another
embodiment, liposomes containing tumor antigens can be embedded in a hydrogel
matrix containing one or more agents involved in differentiation of monocytes
to
dendritic cells, e.g., granulocyte-macrophage colony-stimulating factor,
interleukin-4,
TNFa, and interleukin- 15. Additional factors involved in the differentiation
of
monocytes to dendritic cells are further described in Sabrina Mariotti el al,
The FASEB
Journal. 2008;22:3370-3379, Suresh Kumar, Robert Jack, Journal of Endotoxin
Research, Vol. 12, No. 5, 278-284 (2006) and S. Nagaraj et al, Indian J Med
Res 119,
April 2004, pp 133-138 incorporated herein by reference in its entirety.
Tumor antigens for inclusion in liposomes may be prepared by any method
known in the art suitable for preparing tumor antigens. Such methods include
methods
for extracting and/or purifying polypeptides from a cell or tissue sample,
recombinant
proteins and tumor associated antigens. Particular methods for preparing tumor
antigens
from autologous, allogeneic, syngeneic and other sources are described in the
following
references, incorporated herein by reference in their entirety:
1. Christopher P. Tarassoff, Philip M. Arlen, James L. Gulley. Therapeutic
Vaccines for Prostate Cancer. The Oncologist, Vol. 11, No. 5, 451-462, May
2006;
doi: 10. 1634/theoncologist. 11-5-451
2. Morse MA, Lyerly HK, Gilboa E, Thomas E, Nair SK. Optimization of the
sequence of antigen loading and CD40-ligand-induced maturation of dendritic
cells.
Cancer Res. 1998;58:2965-2968.
3. Mosca PJ, Hobeika AC, Clay TM, et al. A subset of human monocyte-derived
dendritic cells expresses high levels of interleukin-12 in response to
combined CD40
ligand and interferon-gamma treatment. Blood. 2000;96:3499-3504.
4. Morse MA, Coleman RE, Akabani G, Niehaus N, Coleman D, Lyerly HK.
Migration of human dendritic cells after injection in patients with metastatic
malignancies. Cancer Res. 1999;59:56-58.
5. Morse MA, Deng Y, Coleman D, Hull S, et al. A Phase I study of active
immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous
human cultured dendritic cells in patients with metastatic malignancies
expressing
carcinoembryonic antigen. Clin Cancer Res. 1999;5:1331-1338.
6. Li Y, Bendandi M, Deng Y, et al. Tumor-specific recognition of human
myeloma cells by idiotype-induced CD8+ T cells. Blood. 2000;96:2828-2833.
WO 2010/060104 PCT/US2009/065797
7. Banchereau J, Palucka AK, Dhodapkar M, et al. Immune and clinical responses
in patients with metastatic melanoma to CD34+ progenitor-derived dendritic
cell
Vaccine. Cancer Res. 2001;61:6451-6458.
8. Sadanga N, Nagashima H, Mashino K, et al. Dendritic cell vaccination with
MAGE peptide is a novel therapeutic approach for gastrointestinal carcinomas.
Clin
Cancer Res. 2001;7:2277-2284.
9. Fong L, Hou Y, Rivas A, et al. Altered peptide ligand vaccination with F1t3
ligand expanded dendritic cells for tumor immunotherapy. Proc Natl Acad Sci
USA.
2001;98:8809-8814.
10. Toungouz M, Libin M, Bulte F, et al. Transient expansion of peptide-
specific
lymphocytes producing IFN-gamma after vaccination with dendritic cells pulsed
with
MAGE peptides in patients with MAGE-Al/A3-positive tumors. J Leukoc Biol.
2001;69:937-943.
11. Rains N, Cannan RF, Chen W, Stubbs RS. Development of a dendritic cell
(DC)-
based vaccine for patients with advanced colorectal cancer.
Hepatogastroenterology.
2001;48:347-351.
12. Fong L, Brockstedt D, Benike C, Wu L, Engleman EG. Dendritic cells
injected
via different routes induce immunity in cancer patients. J Immunol.
2001;166:4254-
4259.
13. Yu JS, Wheeler CJ, Zeltzer PM, et al. Vaccination of malignant gliomas
patients
with peptide-pulsed dendritic cells elicits systemic cytotoxicity and
intracranial T cell
infiltration. Cancer Res. 2001:61:842-847.
14. Nishiyama T, Tachibana M, Horiguchi Y, et al. Immunotherapy of bladder
cancer using autologous dendritic cells pulsed with human lymphocyte antigen-
A24-
specific MAGE-2 peptide. Clin Cancer Res. 2001;7:23-31.
15. Small EJ, Fratesi P, Reese DM, et al. Immunotherapy of hormone-refractory
prostate cancer with antigen-loaded dendritic cells. J Clin Oncol.
2000;18:3894-3903.
16. Schuler-Thurner B, Dieckmann D, Keikavoussi P, et al. Mage-3 and influenza-
matrix peptide- specific cytotoxic T cells are inducible in terminal stage HLA-
A2.1+
melanoma. J Immunol. 2000 Sep 15;165(6):3492-6.
17. M Jefford a, E Maraskovsky b, J Cebon c, ID Davis d. The use of dendritic
cells
in cancer therapy. The Lancet Oncology, Volume 2, Issue 6, Pages 343 - 353,
June 2001.
26
WO 2010/060104 PCT/US2009/065797
The injectable liposome matrix composition is convertible to a semi-solid
state in
some embodiments, and the injectable composition can be permeable to a product
secreted by monocytic cells that infiltrate the composition and can allow for
monocytic
and dendritic cells to be released from the composition by migration or by
degradation
of the composition. Some embodiments feature injectable compositions that can
be
converted to a semi-solid state by exposing the composition to heat, ionizing
radiation or
ultraviolet radiation. In some embodiments, infiltrating monocytic cells are
capable of
producing more than one product. In some embodiments, the product secreted is
determined by the content of liposomes embedded within the injectible
composition. In
some embodiments, a monocytic cell may be a monocyte precursor cell and may be
a
bone marrow cell and/or a monocyte progenitor cell.
Aspects of the invention include a matrix comprising a hydrogel which may
comprise one or more polymers. In some embodiments, the hydrogel comprises
polylactic acid, polyglycolic acid, other polyhydroxy acids, copolymers of two
or more
polyhydroxy acids, polyorthoesters, polyanhydrides, gelatin, collagen,
cellulose,
derivatized cellulose, chitosan, alginate, thiol-modified hyaluronan, and/or
combinations
or copolymers thereof.
Cross-linkers are comprised by a matrix of the invention in some embodiments.
In particular embodiments, a matrix of the invention comprises one or more of
glutaraldehyde, diphenylphosphoryl azide, transglutaminase, dimethyl
suberimidate,
DMS-treated collagen, dimethyl 3,3'-dithiobispropionimidate, multivalent ions,
calcium
ions, N,N methylene-bisacrylamide (MBA), acrylamide, allyl methacrylate,
ethylene
glycol dimethacrylate, tripolyphosphate, and combinations thereof.
Additional aspects of the invention include methods for recruiting cells
(e.g.,
monocytes) to a localized site in a subject. In some embodiments, a method of
the
invention includes delivering a matrix containing liposomes (i.e., a liposome
matrix) to a
localized site and maintaining the matrix in the localized site for a period
of time
sufficient for cells, e.g., monocytes, to migrate to and/or infiltrate the
localized site. In
some embodiments of the invention, a subject that receives a matrix of the
invention has
a disease, has a condition and/or is at risk for a disease and/or a condition.
In some
embodiments, the disease and/or condition that a subject has or has a risk for
is cancer.
Some aspects of the invention feature a method for treating a subject that has
or
is at risk of having cancer. In some embodiments, a matrix or composition of
the
27
WO 2010/060104 PCT/US2009/065797
invention is administered at or near a site of a tumor. In some embodiments,
the
administration of a matrix or composition results in recruitment of cells
capable of
mediating and promoting a cytotoxic response against tumor cells or against
monocyte
derived dendrtitc cells. In some embodiments, the method for administering the
liposome matrix to a site is by injection.
VII. Induction of Cell Reprogaming
The loss of specific cell function due to a disease or disorder such as an
autoimmune disease, injury, or a genetic defect can have far reaching
implications in
patients, such as, for example, in the cases of diabetes and Parkinson's
disease. In
diabetes, the loss of insulin producing beta cells can lead to high glucose
levels and
multiple damage to cells, tissues, and organs; whereas in Parkinson's disease,
the losso
of dopamine-producing cells can lead to dopamine deficiency, expressed as loss
of
motor function.
One strategy for treating these conditions is by compensating for the loss of
cell
function by delivering the necessary molecules directly to a subject, such as
in the case
of diabetes where insulin is injected directly to the blood. In the case of
Parkinson's
disease, the dopamine precursor L-DOPA is administered to subjects, since
dopamine
itself does not cross the blood-brain barrier.
The permanent need for insulin in diabetes patients, and for dopamine in
Parkinson's disease patients, makes treatment by administration of the
necessary
molecules inconvenient and less than optimally effective.
A treatment that will result in replacing the lost cell function with
functioning
cells that will supply the body with the lost protein, e.g., a hormone or a
neurotransmitter, is more effective and provides greater therapeutic benefits
to a
patient's health and quality of life.
Adult cell reprogramming is the concept of transforming cells from one
specific
subset into a different subset. Such reprogramming can be, for example,
turning skin
fibroblasts into undifferentiated stem cells with the potential to
differentiate into many
different cell types, or the reprogramming of skin fibroblasts into a
different cell type,
such as insulin secreting beta cells, without turning the skin fibroblast into
an
undifferentiated stem cell.
28
WO 2010/060104 PCT/US2009/065797
Different transcription factors have been described which are involved in cell
reprogramming. Reprogramming somatic cells to a pluripotent embryonic state
involves
key transcription factors, including, for example, Oct4, Sox2, c-Myc, klf-4
and Nanog.
These factors, together with Polycomb group (PcG) proteins, regulate other
transcription
factors important for cell differentiation. Transcription factors useful for
reprogramming
ectoderm include, for example, PAX6, MEIS1, and OTX1. Transcription factors
useful
for reprogramming endoderm include, for example, ATBF1. Transcription factors
useful for reprogramming mesoderm include, for example, DLX5, HAND 1, and
OENCUTI.
The present invention is based, at least in part, on the discovery that
monocytes
can be reprogrammed to other cell types that have therapeutic utility in
treatment of
diseases. For example, monocytes can be reprogrammed to become insulin-
secreting
beta cells, or dopamine producing cells.
Monocytes are a type of leukocyte, or white blood cell, which have an integral
role in the innate immune system. Following the appearance of signals
delivered from a
specific site in the body, monocytes are mobilized by chemotactic signals and
adhere to
the activated endothelium through interactions mediated by adhesion molecules
including P-CAM, V-CAM and I-CAM on endothelial cells and CD18 and CD11B on
monocytes. Following their adhesion to the endothelium, monocytes transmigrate
into
the tissue and differentiate into macrophages.
Together with neutrophils, eosinophils and natural killer cells, monocytes
function as a first-line defense to detect, eliminate or contain invading
microbes and
toxic macromolecules. Monocytes responses towards these targets are rapid and
triggered by structures, commonly referred to as Pathogen-Associated Molecular
Patterns (PAMP). Whenever the innate immunity is unable to handle an invading
microorganism, monocytes function as effector cells of the adaptive immune
system,
after receiving the appropriate activation and information from antigen-
specific T and B-
lymphocytes.
Monocytes also have essential functions in wound healing and resolution of
inflammation, mediating cell migration, extra-cellular matrix remodeling and
angiogenesis, all of which are required for tissue repair.
Consequently, an ultimate goal of monocytes is the maintenance of tissue
homeostasis and integrity. This is achieved by various monocyte functions,
such as,
29
WO 2010/060104 PCT/US2009/065797
secretion of specific proteins, scavenging, elimination of pathogen and tumor
cells,
clearance of senescent cells, control of tissue cell growth and modulation of
the extra-
cellular milieu.
To accomplish these tasks, monocytes exhibit a highly flexible gene expression
program that allows them to adapt and respond to changes in their surrounding
micro-
environment, as well as to recruit, engage and coordinate other cell types in
restoring
normal tissue structure and function. These various monocyte activities are
not
displayed concomitantly and, in fact, some of these activities are clearly
contradictory
(e.g., degradation versus synthesis of extracellular matrix). Thus, tissue
monocytes are
functionally heterogeneous under basal conditions, and exhibit a large degree
of
variability upon activation by endogenous factors or exogenous stimuli (see
Vega, MA
et al, Inmunologia 2006, 25(4): 248-272).
Monocyte implantation at site of ischemic tissue has been attempted as a
therapeutic approach for the treatment of various conditions such as cancer,
heart
disease, ischemia, nerve injury, wound healing and diabetes. Similarly,
monocyte
therapy has been used for the delivery of therapeutic proteins by genetic
manipulation,
activation or transformation of the monocytes (Muhlebach, M.D., et al., Mol
Ther, 2005.
12:1206-16; Lu, Y., et al., Cell Mol Biol, 2003. 49:1151-6; Spiekermann, K.,
et al., Eur J
Haematol, 2001. 67:63-71; US 2006/0257359). The use of monocytes has also been
described for nerve repair and spinal cord injury treatment (Lazarov-Spiegler,
0.,
Solomon, A.S., and Schwartz, M. Glia, 1998. 24:329-37; Rapalino, 0., et al.,
Nat Med,
1998. 4:814-21; Schwartz, M., et al., Neurosurgery, 1999. 44:1041-6; U.S.
Patent No.
6,267,955).
While some progress has been made in the field of cellular therapy and
therapeutic protein delivery for tissue repair, there exists a need to improve
the ability to
manipulate monocyte behavior in vivo.
The present invention is based on the development of compositions and methods
for delivery of compounds encapsulated in liposomes. Embodiments of the
invention
feature liquid, semi-solid and solid matrices containing embedded liposomes,
and
methods for their formation and use. Through phagocytosis, monocytes
infiltrating the
matrix selectively incorporate the liposomes and their contents. The matrices
may be
injectable or implantable.
WO 2010/060104 PCT/US2009/065797
In exemplary embodiments, liposomes are introduced to a matrix (hydrogel) and
are embedded in the matrix. The matrix can include one or more agents for
recruiting
cells (e.g., monocytes) to the matrix. Liposomes may be incubated with agents
before
being contacted with a matrix of the invention in some embodiments. In some
embodiments, a matrix of the invention is formulated to incorporate agents and
compounds that exert one or more effects upon cells which infiltrate the
matrix. In other
embodiments, a matrix of the invention is formulated to incorporate agents and
compounds that attract cells (e.g., monocytes) to the matrix. In additional
embodiments,
the matrix is permeable to compounds produced by infiltrating cells. Compounds
produced or secreted by cells within a matrix may diffuse out of the matrix
and create
effects in the surrounding environment in some embodiments. Additional
embodiments
of the invention include kits comprising a matrix of the invention and
instructions for
practicing the invention. In some embodiments, a kit of the invention includes
matrix
and one or more reagents for preparing liposomes for incorporation therein.
One embodiment of the invention features an implantable, semi-solid matrix
comprising a hydrogel material and liposomes embedded therein. In particular
embodiments, the matrix contains one or more agents useful in recruiting
cells, e.g.,
monocytic cells, to a site of implantation. In other embodiments, the
liposomes
embedded in the matrix contain one or more agents which modify or modulate a
behavior of monocytic cells. The behavior modified or modulated in this manner
includes, but is not limited to, secretion of products produced by monocytic
cells.
Additional embodiments of the invention feature an injectable composition
comprising a hydrogel material and liposomes that are added to the injectable
composition, where the liposomes include one or more agents which modify or
modulate
a behavior of monocytic cells. Such material includes, but is not limited to,
expression
vectors encoding one or more transcription factors which function in
differentiation
and/or reprogramming of monocytic cells, e.g., monocytes. These transcription
factors
include, for example, Oct4, Sox2, c-Myc, klf-4, Nanog. Polycomb group (PcG)
proteins, PAX6, MEIS1, OTX1, ATBF1, DLX5, HAND 1, Nuclear factor kappa-B and
OENCUTI. Addditional transcription factors that can function in
differentiation and/or
reprogramming which may be incorporated in expression vectors encapsulated
within
liposomes are described in: Transcription Factors, Series : Handbook of
Experimental
Pharmacology, Vol. 166, by Manfred Gossen (Editor), Jorg Kaufmann (Editor),
Steven
31
WO 2010/060104 PCT/US2009/065797
J. Triezenberg (Editor), Springer, 2004, the entire contents of which are
incorporated
herein by reference. Following injection of the hydrogel composition,
monocytic cells
infiltrating the matrix can phagocytose the liposomes contained therein,
thereby
resulting in expression of the exogenous transcription factors, and
differentiation or
reprogramming into a cell type having altered phenotypic characteristics. In
exemplary
embodiments, the monocytic cells are reprogrammed into insulin-secreting beta
cells or
dopamine-producing cells.
The injectable composition is convertible to a semi-solid state in some
embodiments, and the injectable composition can be permeable to a product
secreted by
monocytic cells that infiltrate the composition. Some embodiments feature
injectable
compositions that can be converted to a semi-solid state by exposing the
composition to
heat, ionizing radiation or ultraviolet radiation. In some embodiments,
infiltrating
monocytic cells are capable of producing more than one product. In some
embodiments,
the product secreted is determined by the content of liposomes embedded within
the
injectible composition. In some embodiments, a product secreted by a monocytic
cell
following reprogramming is insulin. In other embodiments, a product secreted
by a
monocytic cell following reprogramming is dopamine. In some embodiments, a
monocytic cell may be a monocyte precursor cell and may be a bone marrow cell
and/or
a monocyte progenitor cell in some embodiments.
Aspects of the invention include a matrix comprising a hydrogel which may
comprise one or more polymers. In some embodiments, the hydrogel comprises
polylactic acid, polyglycolic acid, other polyhydroxy acids, copolymers of two
or more
polyhydroxy acids, polyorthoesters, polyanhydrides, gelatin, collagen,
cellulose,
derivatized cellulose, chitosan, alginate, thiol-modified hyaluronan, and/or
combinations
or copolymers thereof.
Cross-linkers are comprised by a matrix of the invention in some embodiments.
In particular embodiments, a matrix of the invention comprises one or more of
glutaraldehyde, diphenylphosphoryl azide, transglutaminase, dimethyl
suberimidate,
DMS-treated collagen, dimethyl 3,3'-dithiobispropionimidate, multivalent ions,
calcium
ions, N,N methylene-bisacrylamide (MBA), acrylamide, allyl methacrylate,
ethylene
glycol dimethacrylate, tripolyphosphate, and combinations thereof.
Additional aspects of the invention include methods for recruiting cells
(e.g.,
monocytes) to a localized site in a subject. In some embodiments, a method of
the
32
WO 2010/060104 PCT/US2009/065797
invention includes delivering a matrix containing liposomes (i.e., a liposome
matrix) to a
localized site and maintaining the matrix in the localized site for a period
of time
sufficient for cells, e.g., monocytes, to migrate to and/or infiltrate the
localized site. In
some embodiments of the invention, a subject that receives a matrix of the
invention has
a disease, has a condition and/or is at risk for a disease and/or a condition.
In some
embodiments, the disease and/or condition that a subject has or has a risk for
is diabetes
or Parkinson's disease.
Some aspects of the invention feature a method for treating a subject that has
or
is at risk of having diabetes or Parkinson's disease. In some embodiments, a
matrix or
composition of the invention is administered to the pancreas. In some
embodiments, the
administration of a matrix or composition results in recruitment of cells
capable of
secreting insulin for a time sufficient to prevent or lessen the effects of
diabetes. In
some embodiments, a method for treating a subject that has or is at risk for
diabetes is
featured. In other embodiments, a matrix or composition of the invention is
administered to the brain. In some embodiments, the administration of a matrix
or
composition results in recruitment of cells capable of secreting dopamine for
a time
sufficient to prevent or lessen the effects of Parkinson's disease. In some
embodiments,
the method for administering the liposome matrix to a site is by injection.
In one embodiment, the present invention describes materials and methods for
the local reprogramming of cells in a location where treatment is applied. The
compositions and methods of the invention can be used to replace lost cells or
lost cell
function due to disease, injury or genetic defect. Compositions include a
semisolid
hydrogel matrix embedded with liposomes. The liposomes contain an effector
molecule
or molecules that can induce the reprogramming of cells. When phagocytic cells
such as
monocytes infiltrate the hydrogel following implantation into a subject, they
encounter
the liposomes and incorporate the liposomes carrying the effector molecules
into the
cells. The effector molecules can be genetic material encoding the expression
of
specific proteins such as transcription factors, the expression of which can
initiate the
reprogramming of the cell. The matrix can contain other effector molecules
designed to
attract specific cells to the matrix or to support the reprogramming process.
The
reprogrammed cells can be released from the matrix as the matrix degrades or
by the
motility of the cells. The reprogrammed cells can also remain in the matrix
and secrete
33
WO 2010/060104 PCT/US2009/065797
molecules such as proteins and hormones that will diffuse through the matrix
material to
the surrounding tissue.
The methods and compositions of the invention may be used to induce the
reprogramming of monocytes. This can be used to treat conditions in which
there is a
loss of specifc cells or cell function, such as, for example, in diabetes and
Parkinson's
disease, although the methods and compositions of the invention can also be
used in the
treatment of other conditions where specific cells or cell function is
desired. Typically
the hydrogel will be delivered to the tissue where a cell type or cell
function needs to be
restored, but can also be delivered to connective tissues, internal organs,
and spaces
between tissues or organs. Induction of monocyte reprogramming may be achieved
by
implanting in a tissue a permeable semisolid matrix embedded with liposomes
containing expression vectors which encode specific transcription factors.
Expression of
these transcription factors within the monocyte will induce reprogramming into
the
desired cell type. Transcription factors that trigger monocyte reprogramming
into beta
cells include Ngn3, Pdx1 and Mafa. Matrix infiltrating monocytes will
phagocyte the
liposomes, and the cells then reprogram to become beta cells that produce
insulin and
are capable of compensating for insulin deficiency in an insulin resistant or
insulin
deficient subject. Transcription factors that trigger monocyte reprogramming
into
dopamine secreting cells include one or more of the following: Oct4, Sox2, c-
Myc, klf-
4, Nanog. Polycomb group (PcG) proteins, PAX6, MEIS1, OTX1, ATBF1, DLX5,
HAND I, Nuclear factor kappa-B and OENCUTI.
Additional transcription factors that may be incorporated into liposomes for
delivery in accordance with the methods of the invention are described in Qiao
Zhou,
Juliana Brown, Andrew Kanarek, Jayaraj Rajagopal & Douglas A. Melton. In vivo
reprogramming of adult pancreatic exocrine cells to (3-cells. Nature 455, 627-
632 (2
October 2008), the entire contents of which are incorporated herein by
reference.
Additional transcription factors that may be incorporated into liposomes for
delivery in accordance with the methods of the invention are likewise
described in the
following, the entire contents of which are incorporated herein by reference:
Hanna J, Markoulaki S, Schorderet P, Carey BW, Beard C, Wernig M,
Creyghton MP, Steine EJ, Cassady JP, Foreman R, Lengner CJ, Dausman JA,
Jaenisch
R. (2008) Direct reprogramming of terminally differentiated mature B
lymphocytes to
pluripotency. Cell. 133(2):250-64.
34
WO 2010/060104 PCT/US2009/065797
Wernig M, Zhao JP, Pruszak J, Hedlund E, Fu D, Soldner F, Broccoli V,
Constantine-Paton M, Isacson 0, Jaenisch R. (2008) Neurons derived from
reprogrammed fibroblasts functionally integrate into the fetal brain and
improve
symptoms of rats with Parkinson's disease. Proc Natl Acad Sci U S A.
105(15):5856-61.
Hanna J, Wernig M, Markoulaki S, Sun CW, Meissner A, Cassady JP, Beard C,
Brambrink T, Wu LC, Townes TM, Jaenisch R. Treatment of sickle cell anemia
mouse
model with iPS cells generated from autologous skin. (2007) Science.
318(5858):1920-
3.
Wernig M, Meissner A, Foreman R, Brambrink T, Ku M, Hochedlinger K,
Bernstein BE, Jaenisch R. In vitro reprogramming of fibroblasts into a
pluripotent ES-
cell-like state. (2007) Nature. 19;448(7151):318-24.
Levy YS, Stroomza M, Melamed E, Offen D. Embryonic and adult stem cells as
a source for cell therapy in Parkinson's disease. J Mol Neurosci.
2004;24(3):353-86
Yamanaka S. Induction of pluripotent stem cells from mouse fibroblasts by four
transcription factors. Cell Prolif. 2008 Feb;41 Suppl 1:51-6
Erceg S, Lainez S, Ronaghi M, Stojkovic P, Perez-Arago MA, Moreno-Manzano
V, Moreno-Palanques R, Planells-Cases R, Stojkovic M. Differentiation of human
embryonic stem cells to regional specific neural precursors in chemically
defined
medium conditions. PLoS ONE. 2008 May 7;3(5):e2122.
The present invention features methods and compositions for endogenous cell
therapy which employ an implantable matrix embedded with liposomes. Through
phagocytosis, monocytes infiltrating the matrix selectively incorporate the
liposomes
and their contents. Accordingly, by incorporating liposomes containing
specific
compounds inside an implantable matrix, it it possible to deliver compounds to
monocytes and modulate monocyte behavior.
In one aspect, the invention provides an implantable, semisolid matrix
comprising a hydrogel material and liposomes embedded therein, wherein the
liposomes
contain at least one bioactive material, and wherein the matrix is permeable
to the
infiltration of cells from an implantation environment and to products
secreted from the
cells into the environment. In one embodiment of this aspect, the bioactive
material is
selected from the group consisting of a protein, a peptide, a nucleotide, a
DNA, a RNA,
a siRNA, and a cDNA, or a combination thereof. In another embodiment, the
bioactive
WO 2010/060104 PCT/US2009/065797
material is a small molecule, a drug or a combination thereof. In another
embodiment,
the liposomes contain more than one bioactive material. In an exemplary
embodiment,
the more than one bioactive materials include a biological and a chemical
material.
In another embodiment of this aspect, the liposomes carry the material in the
liposomal hydrophilic core, in the membrane on its surface or in a combination
thereof.
In yet another embodiment, the hydrogel contains a biological or chemical
compound
that is not carried within the liposomes. In one embodiment, the biological or
chemical
compound is a chemoattractant protein. In another embodiment, the
chemoattractant
protein is monocyte chemotactic protein-1.
In one embodiment, the liposomes are attached to the hydrogel matrix by a
chemical bond, e.g., a peptide bond or an ionic bond. In another embodiment,
the
hydrogel material contains cells added to the hydrogel material prior to its
implantation
in the body. In one embodiment, the cells are monocytes.
In another embodiment, the hydrogel of the matrix comprises copolymers of two
or more polyhydroxy acids, polyorthoesters, polyanhydrides, gelatin, collagen,
cellulose,
derivatized cellulose, chitosan, alginate, hyaluronan, thiol-modified
hyaluronan, and
combinations or copolymers thereof. In one embodiment, the polyhydroxy acid is
polylactic acid, polyglycolic acid or other polyhydroxy acid.
In one embodiment, the matrix further comprises a cross-linking agent. In one
embodiment, the cross-linking agent is glutaraldehyde, diphenylphosphoryl
azide,
transglutaminase, dimethyl suberimidate, DMS-treated collagen, dimethyl 3,3'-
dithiobispropionimidate, multivalent ions, calcium ions, N,N methylene-
bisacrylamide
(MBA), acrylamide, allyl methacrylate, ethylene glycol dimethacrylate, or
tripolyphosphate, or combinations thereof.
In some embodiments, the bioactive material contained within the liposomes is
an expression vector encoding a transcription factor. In some embodiments, the
transcription factor is capable of differentiating the cell into an insulin
producing cell. In
exemplary embodiments, the transcription factor is selected from the group
consisting of
NGN-3, PDX-1, MAFA, Oct4, Sox2, c-Myc, klf-4, Nanog. Polycomb group (PcG)
proteins, PAX6, MEIS1, OTX1, ATBF1, DLX5, HAND 1, Nuclear factor kappa-B and
OENCUTI.
In another aspect, the invention features a method for programming an
implantable, semisolid matrix comprising a hydrogel material and liposomes
embedded
36
WO 2010/060104 PCT/US2009/065797
therein to affect the behavior of cell, comprising formulating within the
liposomes a
compound capable of affecting the cell's behavior, such that the cell
infiltrates the
semisolid matrix comprising the hydrogel material and takes up the liposomes
through
phagocytosis or through fusion of the liposome membrane with the cell
membrane.
In another aspect, the invention features a method for effecting the behavior
of a
cell at or near a site of implantation in a subject, comprising implanting at
the site an
implantable, semisolid matrix comprising a hydrogel material and liposomes
embedded
therein, wherein the liposomes comprise at least one compound capable of
affecting the
cell's behavior, such that the cell infiltrates the semisolid matrix
comprising the
hydrogel material and takes up the liposomes through phagocytosis or through
fusion of
the liposome membrane with the cell membrane.
In one embodiment of the foregoing aspects, the behavior is differentiation
and/or reprogramming. In an exemplary embodiment, the behavior is
differentiation
into insulin producing cells. In another exemplary embodiment, the behavior is
differentiation into dopamine producing cells. In various embodiments, the
cell is, for
example, a monocyte, a stem cell, or a stem cell precursor. In exemplary
embodiments,
the site of implantation of the matrix is within the pancreas or within the
brain.
In other embodiments of the foregoing aspects, the compound capable of
affecting the cell's behavior is an expression vector. In an exemplary
embodiment, the
expression vector encodes a transcription factor capable of differentiating
the cell into an
insulin producing cell. In exemplary embodiments, the transcription factor is,
for
example, NGN-3, PDX-1, MAFA, Oct4, Sox2, c-Myc, klf-4, Nanog. Polycomb group
(PcG) proteins, PAX6, MEIS1, OTX1, ATBF1, DLX5, HAND 1, Nuclear factor kappa-
B, OENCUTI, or a combination thereof.
In another aspect, the invention features a method for promoting insulin
secretion
at a localized site in a subject comprising, providing at the localized site
an implantable,
semisolid matrix comprising a hydrogel material and liposomes embedded
therein,
wherein the liposomes comprise an expression vector encoding a transcription
factor
capable of differentiating a cell into an insulin producing cell, and
maintaining the
matrix or composition at the localized site for a period of time sufficient
for a cell to
infiltrate the matrix and phagocytose the liposomes, such that the
transcription factor is
expressed in the cell, thereby promoting differentiation of the cell to
produce insulin at
37
WO 2010/060104 PCT/US2009/065797
the localized site. In an exemplary embodiment, the subject is an insulin
resistant
subject or an insulin deficient subject.
VIII. Articles of Manufacture
The present invention provides kits that comprise a hydrogel material,
reagents
for making liposomes, and instructions for the use of the hydrogel material to
form a
semi-solid matrix comprising liposomes embedded within. In some embodiments,
the
kit includes liposome reagents including, but not limited to, a phospholipid
e.g.,
distearoyl-phosphatidylglycerol (DSPG), 1,2-distearoyl-sn-glycero-3-
phosphocholine
(DSPC), dioleoyl phosphatidyl choline (PC), phosphatidic acid (PA), and/or
phosphatidylglycerol (PG). In other embodiments, the kit includes one or more
of the
saturated lipids Dimyristoylphosphatidylcholine (DMPC), dipalmitoyl
phosphatidylcholine (DPPC), dipalmitoyl phosphatidic acid (DPPA), and
dipalmitoyl
phosphatidylglycerol (DMPG). In exemplary embodiments, stearylamine is used
when
cationic liposomes are preferred. and natural acidic lipids, such as
phosphatidylserine
(PS), PG, phosphatidylinositol (PI), PA, and cardiolipin (CL) are added when
anionic
liposomes are desired. In exemplary embodiments, cholesterol can be included
to
stabilize the bilayer. In exemplary embodiments, small amounts of
antioxidants,
including but not limited to a-tocopherol or 0-hydroxytoluidine (BHT), can be
included
when polyunsaturated neutral lipids are used.
In some embodiments, the kit includes instructions for producing liposomes. In
other embodiments, the instructions describe particular biological or chemical
compounds that may be incorporated into the liposomes. The instructions can
additionally describe particular biological or chemical compounds that are
preferably
selected for incorporation into the liposomes to modulate a particular
behavior of
phagocytic cells, e.g., monocytes. In some embodiments, a kit comprises a
cross-linking
agent for cross-linking the hydrogel to form a semi-solid matrix. In some
embodiments,
a kit includes instructions for combining the hydrogel material, liposomes
and, in
particular embodiments, a cross-linking agents, such that an injectable liquid
is formed
that transitions to a semi-solid matrix following injection into a subject. In
some
embodiments, instructions are provided in a kit of the invention for including
one or
more agents capable of recruiting cells, e.g., monocytic cells, to the matrix.
38
WO 2010/060104 PCT/US2009/065797
Aspects of the invention include kits that comprise one or more hydrogels, and
may comprise polylactic acid, polyglycolic acid, other polyhydroxy acids,
copolymers of
two or more polyhydroxy acids, polyorthoesters, polyanhydrides, gelatin,
collagen,
cellulose, derivatized cellulose, chitosan, alginate, thiol-modified
hyaluronan, and/or
combinations thereof. In some embodiments, a cross-linking agent is comprised
by a kit
of the invention and may comprise glutaraldehyde, diphenylphosphoryl azide,
transglutaminase, dimethyl suberimidate, DMS-treated collagen, dimethyl 3,3'-
dithiobispropionimidate, multivalent ions, calcium ions, N,N methylene-
bisacrylamide
(MBA), acrylamide, allyl methacrylate, ethylene glycol dimethacrylate, and
tripolyphosphate.
Further embodiments of the invention include a kit comprising a hydrogel
material, reagents for making liposomes, and instructions for the use of the
hydrogel
material to form a semi-solid matrix comprising liposomes embedded within. In
some
embodiments, the kit includes liposome reagents including, but not limited to,
a
phospholipid e.g., distearoyl-phosphatidylglycerol (DSPG), 1,2-distearoyl-sn-
glycero-3-
phosphocholine (DSPC), dioleoyl phosphatidyl choline (PC), phosphatidic acid
(PA),
and/or phosphatidylglycerol (PG). In other embodiments, the kit includes one
or more
of the saturated lipids Dimyristoylphosphatidylcholine (DMPC), dipalmitoyl
phosphatidylcholine (DPPC), dipalmitoyl phosphatidic acid (DPPA), and
dipalmitoyl
phosphatidylglycerol (DMPG). In exemplary embodiments, stearylamine is used
when
cationic liposomes are preferred. and natural acidic lipids, such as
phosphatidylserine
(PS), PG, phosphatidylinositol (PI), PA, and cardiolipin (CL) are added when
anionic
liposomes are desired. In exemplary embodiments, cholesterol can be included
to
stabilize the bilayer. In exemplary embodiments, small amounts of
antioxidants,
including but not limited to a-tocopherol or 0-hydroxytoluidine (BHT), can be
included
when polyunsaturated neutral lipids are used.
In some embodiments, the kit may additionally include a buffer suitable for
use
in preparing liposomes (e.g., 0.9% NaC1). In some embodiments, a kit comprises
a
cross-linking agent for cross-linking the hydrogel to form a semi-solid
matrix. In some
embodiments, a kit includes instructions for combining the hydrogel material,
liposomes
and, in particular embodiments, one or more cross-linking agents, such that an
injectable
liquid is formed that transitions to a semi-solid matrix following injection
into a subject.
39
WO 2010/060104 PCT/US2009/065797
In some embodiments, instructions are provided in a kit of the invention for
including
one or more agents capable of recruiting cells, e.g., monocytic cells, to the
matrix.
Additional aspects of the invention include kits that comprise one or more
hydrogels, and may comprise polylactic acid, polyglycolic acid, other
polyhydroxy
acids, copolymers of two or more polyhydroxy acids, polyorthoesters,
polyanhydrides,
gelatin, collagen, cellulose, derivatized cellulose, chitosan, alginate, thiol-
modified
hyaluronan, and/or combinations thereof. In some embodiments, a cross-linking
agent
provided with a kit of the invention may comprise glutaraldehyde,
diphenylphosphoryl
azide, transglutaminase, dimethyl suberimidate, DMS-treated collagen, dimethyl
3,3'-
dithiobispropionimidate, multivalent ions, calcium ions, N,N methylene-
bisacrylamide
(MBA), acrylamide, allyl methacrylate, ethylene glycol dimethacrylate, and
tripolyphosphate.
In particular embodiments, the kits, or articles of the invention further
comprise
one or more bioactive molecules or chemical compounds for incorporation into
the
liposome matrix.
IX. Polycaprolactone Particles as Scaffolds for Tissue Regeneration
Tissue engineering involves a combination of cells, engineering and materials
methods, and suitable biochemical and physio-chemical factors to improve or
replace
biological functions. In practice, tissue engineering is closely associated
with
applications that repair or replace portions of or whole tissues (i.e., bone,
cartilage,
blood vessels, bladder, etc.). Often, the tissues involved require certain
mechanical and
structural properties for proper functioning.
Scaffolds are artificial structures capable of supporting three-dimensional
tissue
formation. Scaffolds usually serve at least one of the following purposes:
allowing cell
attachment and migration; delivering and retaining cells and biochemical
factors;
enabling diffusion of vital cell nutrients and expressed products; or exertion
of certain
mechanical and biological influences to modify the behavior of the cell phase.
To achieve the goal of tissue reconstruction, scaffolds must meet some
specific
requirements. A high porosity and an adequate pore size are necessary to
facilitate cell
seeding and diffusion throughout the whole structure of both cells and
nutrients.
Biodegradability is often an essential factor since scaffolds should
preferably be
absorbed by the surrounding tissues without the necessity of a surgical
removal.
WO 2010/060104 PCT/US2009/065797
In one embodiment, the present invention relates to methods of using
polycaprolactone (PCL) particles as biodegradable scaffolds in tissue
engineering
applications.
In one embodiment, the application is directed to methods of promoting tissue
regeneration, the method comprising contacting a localized area of tissue with
solvent-
free polycaprolactone (PCL) particles.
In another embodiment, the application is directed to a dermal filler
comprising a
solvent-free polycaprolactone (PCL) scaffold for the attachment of skin
fibroblasts.
In another embodiment, the application is directed to an angiogenic hydrogel
comprising a solvent-free polycaprolactone (PCL) scaffold and one or more of
copolymers of two or more polyhydroxy acids, polyorthoesters, polyanhydrides,
gelatin,
collagen, cellulose, derivatized cellulose, chitosan, alginate, hyaluronan,
thiol-modified
hyaluronan, and combinations or copolymers thereof.
In the present invention, PCL is used to generate the micro-particles. PCL is
a
biocompatible and biodegradable polymer. In the present invention, the micro
particles
are generated with PCL by means of physical methods such as grinding, milling,
chopping and/or molding the polymer base material, and without using organic
solvents.
0
II
":~ ,= .. ..: f= r. -.`;:,% .,~::;_ OCH2CH2CH2CH2CH2C
polycaprolactone polycaprolactone
Methods for the production of PCL particles are descrioeu y u . (P.
Iooss. Biomaterials. Volume 22, Issue 20, 15 October 2001, Pages 2785-2794 ;
M.
Lebourg. J Mater Sci: Mater Med (2008) 19:2047-2053 ; Lim Liang Kuang. Journal
of
Controlled Release. Volume 102, Issue 2, 2 February 2005, Pages 395-413.)
The methods described in the art for the production of PCL particles include
the
use of an organic solvent, which makes it unpractical for clinical use in
tissue
regeneration applications. After using organic solvent in the production, some
traces of
it may remain in the final product, which may have a potentially hazardous
effect on the
safety of the polymer in vivo, when the polymer is expected to stay in vivo
for a long
time (more than one month). Currently, PCL particles created with organic
solvents are
used for controlled drug delivery, where the particle will stay in vivo for
only a few
days, or for coating medical devices in conjunction with other materials in
which
immunosuppressants are given to prevent an immune response.
41
WO 2010/060104 PCT/US2009/065797
In the present invention, the production of PCL particles is performed by
physical processes and without the use of organic solvents. PCL particles are
generated
by means of physical processes such as grinding, milling chopping and/or
molding the
polymer base material, as described, for example, in WO/1993/006267 which is
hereby
incorporated by reference for he purpose of teaching such processes.
After processing PCL into particles the particles can be filtered to
restricted size in
order to obtain maximum particle size. The minimal size of a particle will be
determined
by the thickness of the filament used.
The PCL particles can then be assembled in a way that will serve as a
scaffold. In
one of the embodiments, the PCL particles have a rod shape, and are aggregated
in a hay
bed manner.
In another embodiment the PCL particles are embedded within a hydrogel matrix
such as collagen or hyaluronic acid that help hold the particles in place
following their
delivery in the body.
In another embodiment the PCL particles serve as a bed for the attachment of
fibroblasts
In one embodiment, the invention is related to a method of promoting tissue
regeneration, the method comprising contacting a localized area of tissue with
solvent-
free polycaprolactone (PCL) particles. In an exemplary embodiment the PCL
particle
size ranges from 1-1000 microns, for example 5-50 microns.
In another embodiment the PCL particles are processed by grinding, milling,
chopping and/or molding.
In one embodiment the PCL particles are embedded within a hydrogel. The
hydrogel comprises one or more copolymers comprising two or more polymers
selected
from polyhydroxy acids, polyorthoesters, polyanhydrides, gelatin, collagen,
cellulose,
derivatized cellulose, chitosan, alginate, hyaluronan, thiol-modified
hyaluronan, and
combinations or copolymers thereof.
In one embodiment, the tissue is contacted by surgical implantation. In
another
embodiment, the tissue is contacted by injection. In yet another embodiment,
the tissue
is contacted by topical application.
In an exemplary embodiment, the localized area of tissue is selected from
physically wounded, necrotic, ischemic or dermal tissue. In a preferred
embodiment, the
localized area of tissue is dermal tissue.
42
WO 2010/060104 PCT/US2009/065797
In one embodiment of the invention, the polycaprolactone (PCL) particles are
used in the production of scaffolds for dermal fillers in cosmetic
interventions. In this
embodiment, the particles should comply with the following requirements:
(1) Biocompatibility, not inducing an immune response and generating only
minimal
inflammation;
(2) Have good shape memory in order to maintain shape while the product is
injected under the skin;
(3) Have good shape memory so that injected locations will retain shape for a
long
period of time (1-24 months, preferably 12-18 months) under the skin, where
mechanical forces are routinely inflicted on the skin. The scaffold material
should be sufficiently stable to last for a predictable period of time without
losing
its dual therapeutic effects a) as filler and b) as a scaffold for attachment
of skin
fibroblasts;
(4) The scaffold within the dermal filler should act as a bed for the
attachment and
propagation of skin fibroblasts. Fibroblasts attached to the scaffold material
will
proliferate, secrete collagen and regenerate the connective tissue in the
wrinkle
area; and/or
(5) The scaffold should degrade slowly over a long period of time, without
disrupting the cells embedded in the scaffold. By the time in which the
scaffold
is completely absorbed (1-24 months, preferably 12-18 months), the connective
tissue produced will remain and therefore will fill the space of the scaffold
after
the scaffold has been absorbed.
In an exemplary embodiment, the dermal filler comprises a solvent-free
polycaprolactone (PCL) scaffold for the attachment of skin fibroblasts.
In another exemplary embodiment, the dermal fillers are an injectable material
used in contouring and volumising facial wrinkles and folds. They can also be
used to
create definition and pouting of the lips.
Dermal fillers are a class of biodegradable scaffolds used to help reverse the
changes associated with aging. As skin ages, the dermis gradually loses its
major
constituents: collagen, elastin and hyaluronic acid. Collagen acts as the
major support
protein for our skin; elastin allows our skin to stay firm and resist
wrinkles; hyaluronic
acid helps to trap water and add volume and shape to our skin. Because the
goal is to
43
WO 2010/060104 PCT/US2009/065797
return the dermis to its original youthful state, dermal fillers can give a
more natural
appearance than surgical face lifts. Dermal fillers are being used to reduce
or eliminate
wrinkles, raise scar depressions, enhance lips, and replace soft-tissue volume
loss.
In other embodiment of the invention, the PCL particles are used in the
production of scaffolds for angiogenic gel-based therapies. The angiogenic gel-
based
therapy can be used in the treatment of limb ischemia, wound healing, tissue
grafting,
ischemic heart disease, ischemic brain, etc. In this embodiment, the particles
should
comply with the following requirements:
(1) Biocompatibility, not inducing an immune response and generating only
minimal
inflammation;
(2) Have good shape memory in order to maintain shape while the product is
injected into the muscle tissue and/or subcutaneous tissue;
(3) Have good shape memory in order to maintain shape for a long period of
time (1-
24 months, preferably 12-18 months or 3-6 months) in muscle tissue or
connective tissue, where mechanical forces are routinely inflicted. The
scaffold
material should be sufficiently stable to last for a predictable period of
time
without losing its therapeutic effect as a mechanical scaffold for the
generation
of 3 dimensional spherical constructs in the place of injection; and/or
(4) The PCL-based scaffold should act as a bed for the attachment of
leucocytes and
in particular monocytes. Leucocytes attached to the scaffold material or
embedded next to the scaffold will have an ischemic micro-environment. For
example, monocytes in an ischemic environment will switch into their
angiogenic phenotype and will secrete a cascade of vascular growth factors
such
as vascular endothelial growth factor into the surrounding tissue, promoting
the
growth of new blood vessels.
In one embodiment, the angiogenic hydrogel comprises a solvent-free
polycaprolactone (PCL) scaffold and a hydrogel comprising one or more
copolymers
comprising two or more polymers selected from polyhydroxy acids,
polyorthoesters,
polyanhydrides, gelatin, collagen, cellulose, derivatized cellulose, chitosan,
alginate,
hyaluronan, thiol-modified hyaluronan, and combinations or copolymers thereof.
In another embodiment, the angiogenic hydrogel is used to treat ischemia, for
example, limb ischemia, ischemic heart disease or ischemic brain. In one
embodiment,
44
WO 2010/060104 PCT/US2009/065797
the angiogenic hydrogel is used to treat wounds. In yet another embodiment,
the
angiogenic hydrogel is used for tissue grafting.
In an exemplary embodiment, the angiogenic gel-based therapy is a hydrogel
composition that promotes the growth of new blood vessels by changing the
phenotype
of cells that infiltrate the hydrogel so they will secret angiogenic growth
factors.
The foregoing disclosure teaches to those of skill in the art the aspects of
the
invention including how to make and use the invention. The following examples
are
meant to provide further elucidation of the invention and are not meant to be
limiting.
WO 2010/060104 PCT/US2009/065797
EXAMPLES
Example 1: Localized differentiation of endogenous monocytes into an
angiogenic
phenotype.
a. Preparation of liposomes containing IL-4 and IL-l0 and liposomes containing
Adenosine.
Reagents
Dioleoyl Phosphatidyl Choline
Saline (0.9% NaCl)
Human recombinant IL-4 and IL-10 are used together to activate the angiogenic
phenotype in monocytes.
Adenosine can be used alone or in combination with IL-4 and IL-10 to activate
the angiogenic phenotype in monocytes.
Method of producing liposomes containing IL-4 and IL-10 for targeting of
monocytes
Under aseptic conditions:
1. Dry 0.5 pmole of dioleoyl phosphatidyl choline under nitrogen in a
disposable
glass tube.
2. Evacuate in dessicator under vacuum for 30 minutes.
3. Add saline to required volume and scrape the sides of the glass tube to
dislodge
the lipid.
4. Add IL-4 and IL-10 1 pg/ l of lipid used, and, optionally adenosine 200 M.
5. Vortex for 30 seconds. Sonicate twice in a bath sonicator at 7 C for 1
min.
This makes multilamellar vesicles that become small unilamellar vesicles (SUV)
with
prolonged sonication time. To make large unilamellar vesicles, use an
extruder.
Method of producing liposomes containing adenosine for targeting of monocytes
Adenosine is encapsulated in liposomes composed of 50 moUL distearoyl-
phosphatidylglycerol (DSPG), 100 moUL cholesterol, and 150 moUL of 1,2-
distearoyl-sn-glycero-3-phosphocholine (DSPC) by reverse-phase evaporation
technique, as described by Monkkonen J, Taskinen M, Auriolal SOK, et al. J
Drug
Target. 1994; 2: 299-308. Liposomes with average size of 150 nm are produced
composed of 0.5 mmol/L, and 20 mmol/L, adenosine and lipids, respectively.
46
WO 2010/060104 PCT/US2009/065797
b. Preparation of the semisolid hydrogel matrix with liposomes for delivery of
liposomes containing IL-4 and IL-l0
Type 1 collagen solution 4mg/ml in saline in neutral pH is freshly prepared
and kept on
ice to delay gelation. 2X10^6 liposomes in 200 1 saline are added to 200 L of
the liquid
collagen and mixed gently. Gelatin powder (e.g., Gelfoam powder) can be added
to the
collagen solution in order to increase and maintain volume in the injection
site and to
increase monocyte attraction. The use of specific monocyte chemoatractents
such as
monocyte chemotactic protein-1 (MCP1) within the matrix can also be used to
attract
monocytes to the matrix. For this purpose, MCP1, 1 g/ml can be incorporated
within
the matrix.
c. Localized delivery of the hydrogel embedded with liposomes
The collagen solution with the suspended liposomes is injected to the patient
where
needed. For example if the differentiation is towards an angiogenic phenotype,
the
delivery will be to an ischemic muscle tissue. The patient's monocytes will
invade the
matrix and phagocyte the liposomes resulting in uptake of the delivered
cytokines or
adenosine and activation/differentiation of the monocytes/macrophages.
Example 2: Presentation of cancer cell antigens to monocytes/dendritic cells
in the
vicinity of a tumor.
a. Preparation of patient specific tumor antigens
Tumor cells are taken by biopsy from a patient. The cells are lysed
mechanically or by
using a surface active material such as triton-X100. If surface antigens from
the patient's
cancer cells are required, cells can be incubated in a hypotonic buffer such
as distilled
water to remove cell content, and protein can then be extracted from the
membranes.
Protein extract from the cells is filtered to remove surface active materials
and
resuspended in saline solution. The protein extract from the cells is used for
loading into
liposomes. Proteins are loaded inside the liposomes to be phagocytosed by
monocytes
infiltrating the implanted matrix.
b. Preparation of the liposomes containing tumor antigens
Reagents
Dioleoyl Phosphatidyl Choline
47
WO 2010/060104 PCT/US2009/065797
Saline (0.9% NaCl)
Method
Under aseptic conditions:
1. Dry 0.5 mole of dioleoyl phosphatidyl choline under nitrogen in a
disposable
glass tube.
2. Evacuate in dessicator under vacuum for 30 minutes.
3. Add Saline to required volume and scrape the sides of the glass tube to
dislodge
the lipid.
4. Add protein extracted from cancer cells at 1 g/ l of lipid used and
macrophage
colony-stimulating factor at 1 g/ l of lipid used.
5. Vortex for 30 seconds. Sonicate twice in a bath sonicator at 7 C for 30
sec.
This makes multilamellar vesicles that become small unilamellar vesicles (SUV)
with
prolonged sonication time. To make large unilamellar vesicles, an extruder can
be used.
Alternative method to produce liposomes containing cancr antigens for
targeting of
monocytes:
Protein is extracted from cancer cells as described above. Protein at 1 g/ l
of
lipid used, and macrophage colony-stimulating factor (GM-CSF) at 1 g/ l of
lipid
used, is encapsulated in liposomes composed of 50 moUL distearoyl-
phosphatidylglycerol (DSPG), 100 moUL cholesterol, and 150 moUL of 1,2-
distearoyl-sn-glycero-3-phosphocholine (DSPC) by reverse-phase evaporation
technique, as described by Monkkonen J, Taskinen M, Auriolal SOK, et al. J
Drug
Target. 1994; 2: 299-308. Liposomes with average size of 150 nm are produced
containing the cancer antigens and (GM-CSF).
c. Preparation of the semisolid hydrogel matrix for delivery of liposomes
containing
tumor antigens
Type 1 collagen solution at 4mg/ml in saline at neutral pH is freshly prepared
and kept
on ice to delay gelation. 10^7 liposomes in 200 1 saline are added to 200 L of
the liquid
collagen and mixed gently. The collagen solution with the suspended liposomes
is
injected to the same patient in the vicinity of the tumor from which the
biopsy was taken
and protein extracted.
48
WO 2010/060104 PCT/US2009/065797
d. Localized delivery of the hydrogel embedded with liposomes containing tumor
antigens
The collagen solution with the suspended liposomes is injected to the patient
in the
vicinity of the tumor. The patient's monocytes will invade the matrix and
phagocytose
the liposomes resulting in uptake of the tumor antigens and
activation/differentiation to
dendritic cells. The dendritic cells will then ether exit the matrix as it
degrades and will
interact with T-cells in their surrounding environment, or will interact with
infiltrating
T-cells in the matrix. The activated T-cells will initiate a cell-mediated
immune response
aimed towards the tumor cells.
Example 3: Localized reprogramming of endogenous monocytes or stem cells into
functional insulin-producing beta cells in the pancreas
a. Preparation of liposomes containing expression vectors that encode
transcription
factors
Reagents
Dioleoyl Phosphatidyl Choline
Saline (0.9% NaCl)
Method
Under aseptic conditions:
1. Dry 0.5 mole of dioleoyl phosphatidyl choline under nitrogen in a
disposable
glass tube.
2. Evacuate in dessicator under vacuum for 30 minutes.
3. Add saline to required volume and scrape the sides of the glass tube to
dislodge
the lipid.
4. Add expression vectors that encode Ngn3, Pdxl and Mafa, 0.1 g/ l of lipid
used.
5. Vortex for 30 seconds. Sonicate twice in a bath sonicator at 7 C for 30
sec.
This makes multilamellar vesicles that become small unilamellar vesicles (SUV)
with
prolonged sonication time. To make large unilamellar vesicles, an extruder can
be used.
Another method to produce liposomes containing transcription factors for
targeting
monocytes:
49
WO 2010/060104 PCT/US2009/065797
Expression vectors encoding Ngn3, Pdxl and Mafa (0.1 g/ l of lipid used) are
encapsulated in liposomes composed of 50 moUL distearoyl-phosphatidylglycerol
(DSPG), 100 moUL cholesterol, and 150 moUL of 1,2-distearoyl-sn-glycero-3-
phosphocholine (DSPC) by reverse-phase evaporation technique. Reverse-phase
evaporation technique is described by Monkkonen J, Taskinen M, Auriolal SOK,
et al. J
Drug Target. 1994; 2: 299-308, incorporated herein by reference in its
entirety.
Liposomes with average size of 150 nm are produced.
b. Preparation of the semisolid hydrogel matrix for delivery of liposomes
containing
transcription factors
Type 1 collagen solution (4mg/ml in saline at neutral pH) is freshly prepared
and kept on
ice to delay gelation. 2X10^6 liposomes in 200 1 saline are added to 200 L of
the liquid
collagen and mixed gently. Gelatin powder (Gelfoam powder can be added to the
collagen solution in order to increase and maintain volume in the injection
site and to
increase monocyte attraction. The use of specific monocyte chemoatractents
such as
monocyte chemotactic protein-1 within the matrix can also be used to attract
monocytes
to the matrix. Alternatively the liposomes can be added to the semisolid
collagen gel
and mixed with the semisolid gel to produce a mixture of gel particles and
liposomes.
c. Localized delivery of the hydrogel embedded with liposomes containing
transcription factors into the pancreas
The collagen solution with the suspended liposomes is injected to the
pancreas. The
patient's monocytes will invade the matrix and phagocyte the liposomes
resulting in
uptake of the delivered transcription factors and the
reprogramming/differentiation into
functional insulin-producing beta cells.
Although the foregoing invention has been described in detail for purposes of
clarity of understanding, it will be obvious that certain modifications may be
practiced
within the scope of the appended claims. All publications and patent documents
cited
herein, as well as text appearing in the figures, are hereby incorporated by
reference in
their entirety for all purposes to the same extent as if each were so
individually denoted.
